SYNTHETIC APPROACHES TO CYCLODEPSIPEPTIDES THE SYNTHESIS OF NORSURFACTIN by CIARDELLI, THOMAS LON
University of New Hampshire
University of New Hampshire Scholars' Repository






Follow this and additional works at: https://scholars.unh.edu/dissertation
This Dissertation is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository. It has
been accepted for inclusion in Doctoral Dissertations by an authorized administrator of University of New Hampshire Scholars' Repository. For more
information, please contact nicole.hentz@unh.edu.
Recommended Citation
CIARDELLI, THOMAS LON, "SYNTHETIC APPROACHES TO CYCLODEPSIPEPTIDES THE SYNTHESIS OF
NORSURFACTIN" (1975). Doctoral Dissertations. 1081.
https://scholars.unh.edu/dissertation/1081
INFORMATION TO USERS
This material was produced from a microfilm copy of the original document. While 
the most advanced technological means to photograph and reproduce this document 
have been used, the quality is heavily dependent upon the quality of the original 
submitted.
The following explanation of techniques is provided to help you understand 
markings or patterns which may appear on this reproduction.
1.The sign or "target" for pages apparently lacking from the document 
photographed is "Missing Page(s)". If it was possible to obtain the missing 
page(s) or section, they are spliced into the film along with adjacent pages. 
This may have necessitated cutting thru an image and duplicating adjacent 
pages to insure you complete continuity.
2. When an image on the film is obliterated with a large round black mark, it 
is an indication that the photographer suspected that the copy may have 
moved during exposure and thus cause a blurred image. You will find a 
good image of the page in the adjacent frame.
3. When a map, drawing or chart, etc., was part of the material being 
photographed the photographer followed a definite method in 
"sectioning" the material. It is customary to begin photoing at the upper 
left hand corner of a large sheet and to continue photoing from left to 
right in equal sections with a small overlap. If necessary, sectioning is 
continued again — beginning below the first row and continuing on until 
complete.
4. The majority of users indicate that the textual content is of greatest value, 
however, a somewhat higher quality reproduction could be made from 
"photographs" if essential to the understanding of the dissertation. Silver 
prints of "photographs" may be ordered at additional charge by writing 
the Order Department, giving the catalog number, title, author and 
specific pages you wish reproduced.
5. PLEASE NOTE: Some pages may have indistinct print. Filmed as 
received.
Xerox University Microfilms
300 North Zeeb Road
Ann Arbor, Michigan 48106
75-19,873
CIARDELLI, Thomas Lon, 1948- 
SYNIHETIC APPROACHES TO CYCLODEPSIPEPTIDES. 
THE SYNTHESIS OF NORSURFACTIN.
University of New Hampshire, Ph.D., 1975 
Chemistry, organic
Xerox University Microfilms, Ann Arbor, Michigan 48106




THE SYNTHESIS OF NORSURFACTIN
by
THOMAS L. CIARDELLI
B.S., Rensselaer Polytechnic Institute, 1970
A THESIS
Submitted to the University of New Hampshire 
In Partial Fulfillment of 
The Requirements for the Degree of 
Doctor of Philosophy 
Graduate School 
Department of Chemistry 
May, 1975
This thesis has been examined and approved.
S.
The^/s Director, James D. Morrison 
Proressor of Chemistry
Kenneth K. Andersen 
Professor of Chemistry
Pad' 01.
Paul R. J o n e s ^  
Professor of Chemistry
Charles W. Owens
Associate Professor of Chemistry
Robert M. Zs;
Assistant Pr<of^sor of Microbiology
Date
ACKNOWLEDGEMENT
The author wishes to express his sincere appreciation 
to his research director, Dr. James D. Morrison, for his 
guidance, support and encouragement during the course of this 
research and for the opportunity to share a unique learning 
experience. Gratitude is expressed to the Department of 
Chemistry, the chemistry faculty and especially to Dr. K. K. 
Andersen, who served as second reader.
The author would like to extend special gratitude 
to Dr. Richard G. Hiskey of the University of North Carolina 
for the opportunity to learn the techniques of peptide 
synthesis in his laboratory.
Sincere appreciation is expressed to the Departments 
of Biochemistry and Microbiology for providing assistance in 
obtaining required analytical data.
The author would like to acknowledge the University 
of New Hampshire, the National Science Foundation and the 
National Institutes of Health for financial assistance during 
the course of this research.
TO MY PARENTS
TABLE OF CONTENTS
LIST OF FIGURES.............................................. viii
















High Pressure Liquid Chromatography............ 118
Thin Layer Chromatography........................ 118
Compound s .......................................... 119
D,L-6-Hydroxytetradecanoic Acid (12J................. 12 0
Resolution of D,L-8-Hydroxytetradecanoic Acid.......121
D ,L-tert-Butyl-p-hydroxytetradecanoate (20 ) ......... 12 2
Benzyloxycarbonyl-L-leucine (2]J......................123
The Attempted Esterification of Benzyloxycarbonyl- 
L-leucine (21 ) with D,L-tert-Butyl-6~ 
hydroxytetradecanoate (20 ). Method A .......... 12 3
Method B ............................................124
Method C ............................................12 4
v
The Esterification of Benzyloxycarbonylglycine 
(23) with D,L-tert-Butyl-B-hydroxytetra- 




The Attempted Esterification of Benzyloxycarbonyl- 
L-leucine (23£ with D,L-Methyl-B-hydroxy- 
tetradecanoate (2_5) . Method A ................... 127
Method B ............................................ 128
The Esterification of Benzyloxycarbonylglycine
(23) with D,L-Methyl-f3-hydroxytetradecanoate
(25) . Method A ....................................12 9
Method B ............................................12 9
D, L-Methyl-B-hydroxybutyrate (28 ) ..................... 130
The Esterification of Benzyloxycarbonylglycine
(23) with D,L-Methyl-8-hydroxybutyrate (28)....130
The Esterification of Benzyloxycarbonyl-L-alanine
(30) with D,L-Methyl-8-hydroxybutyrate (28)...■131
The Esterification of Benzyloxycarbonyl-L-leucine
(21) with D,L-Methyl-[3-hydroxybutyrate (28) .... 131
D-p-Nitrobenzyl-B-hydroxytetradecanoate (D-34)...... 132
L-g-Nitrobenzyl-B-hydroxytetradecanoate (L-34)...... 133
tert-Butoxycarbonyl-D-leucine Monohydrate (35 ) ...... 134
tert-Butoxycarbonyl-leucine Monohydrate (3J7)........ 134
The Esterification of tert-Butoxycarbonyl-D-
leucine (3_5) with L-p-Nitrobenzyl-6-hydroxy- 
tetradecanoate (L-34). Method A .................135
The Esterification of tert-Butoxycarbonyl-L-leucine 
(37) with D-p-Nitrobenzyl-8-hydroxytetra- 
decanoate (D-34)................................... 136
The Preparation of Didepsipeptide 39 .^.................137
The Preparation of Didepsipeptide ^ 0 ..................137
The Preparation of Tridepsipeptide 42^ ................ 13 8
The Preparation of Tridepsipeptide £ 3 ................ 139
The Preparation of Tridepsipeptide £ £ ................ 13 9
The Preparation of Tridepsipeptide £ 5 ................ 14 0
Benzyloxycarbonyl(8-tert-butyl)aspartate (£6)....... 140
vi
8-tert-Butyl Aspartate (47 ) ............................ 140
o-Nitrophenylsulfenyl(6-tert-butyl)aspartate
Dicyclohexylamine Salt (4J3)...................... 141
The Preparation of Tetradepsipeptide 51^ .............. 142
Benzyloxycarbonyl-D-leucine (52 ) ...................... 143









P r e p L i e
A. . -!.............
B. .........
C . . .............
D. . . .................... ...........
Benzyloxycarbonyl ( leucy 1-
D-leucyl-valine ............... 1^2





D-leucyl-valyl(6-tert-butyl)aspartate (64 ) ...... 154
The Preparation of Octadepsipeptide 6JS................ 155
The Preparation of Octadepsipeptide 66^ ................ 156
The Preparation of Octadepsipeptide 67_................ 157
The Preparation of Cyclooctadepsipeptide 6j).......... 157
Norsurfactin (1JJ........................................159
REFERENCES..................................................... 161
B-tert-Butyl Aspartate (47)............................ 140
o-Nitrophenylsulfenyl(6-tert-butyl)aspartate
Dicyclohexylamine Salt (4_9)...................... 141
The Preparation of Tetradepsipeptide 5jL.............. 142
Benzyloxycarbonyl-D-leucine (5^2)...................... 143





Leucyl-D-leucyl-valine Methyl Ester 5J7............... 148
Benzyloxycarbonyl (y-tert-butyl)glutamate (5_8)........ 148
Benzyloxycarbonyl(y-tert-butyl)glutamyl-leucyl-
D-leucyl— aline Methyl Ester (5^9)............... 149
Attempted Preparation of Tetradepsipeptide 60.
Method A ............................................ 150
Method B ............................................ 151
Method C ............................................ 151
Method D ............................................ 152
Benzyloxycarbonyl(y-tert-butyl)glutamyl-leucyl-
D-leucyl-valine (£1).............................. 152






The Preparation of Octadepsipeptide 65^ ................ 155
The Preparation of Octadepsipeptide 66_................ 156
The Preparation of Octadepsipeptide 67^ ................ 157




Figure 1. Serratamolide....................................... 2
Figure 2. Isariin.............................................. 2
Figure 3. Surfactin (B. subtilis)............................ 3
Figure 4. The Structure of Esperin (B. mesentericus)......4
Figure 5. The 6-Hydroxy Fatty Acids Present in Esperin..19
Figure 6. Attempts to Lactonize Isariic Acid to
Isariin............................................ 30
Figure 7. The Preparation of Intermediate 14_ via
Esterification of the Heptapeptide............. 33
Figure 8. The Preparation of Intermeidate 14^  by
Initial Formation of the Ester Bond Followed 
by Lengthening of the Peptide Chain............ 34
Figure 9. The Removal of the N-terminal Protecting
Group on D-leucine, During Elaboration of 
the Peptide Chain.................................36
Figure 10. Removal of the N-terminal Protecting Group
from Aspartic Acid................................36
Figure 11. The Preparation of Benzyloxycarbonyl Amino
Acids...............................................40
Figure 12. The Preparation of tert-Butoxycarbonyl
Amino Acids........................................41
Figure 13. The Use of the Benzyloxycarbonyl Group (Z)
for amino Protection of the First Two Leucine 
Residues........................................... 43
Figure 14. The Preparation of 2-p-Biphenyl-2-propyloxy-
carbonyl Amino Acids............................. 45
Figure 15. The Preparation of o-Nitrophenylsulfenyl
Amino Acids........................................47
Figure 16. The Use of the o-Nitrophenylsulfenyl Group

















The Preparation of Raceraic B-Hydroxytetra- 
decanoic Acid................................
The Preparation of tert-Butyl-3-hydroxy- 
tridecanoate.................................
The Preparation of tert-Butyl-D-B- 
hydroxydodecanoate..........................
The Preparation of Racemic tert-Butyl-B- 
hydroxytetradecanoate.......................
The Formation of the Ester Bond in Step 1 
of the Norsurfactin Synthesis..............
The Formation of a Depsipeptide Bond Using 
Benzenesulfonyl Chloride...................
The Use of N,N'-Carbonyldiimidazole for 
Amino Acid Esterification..................
The Formation of a Depsipeptide Bond Using 
N,N'-Carbonyldiimidazole...................
Depsipeptide Bond Formation Using a B- 
Hydroxy Acid Derivative.....................
The Attempted Esterification of Benzyloxy­
carbonyl-L-leucine with D,L-tert-Butyl-3- 
Hydroxytetradecanoate.......................
The Esterification of Benzyloxycarbonyl­
glycine with D,L-tert-Butyl-B-hydroxy- 
tetradecanoate...............................
The Preparation of D ,L-Methyl-B- 
hydroxytetradecanoate.......................
Esterification Using D ,L-Methyl-B- 
hydroxytetradecanoate.......................
Esterification of Several Z-Amino Acids 
with D,L-Methyi-3-hydroxybutyrate.........
The Preparation of D and L-p-Nitrobenzyl- 
B-hydroxytetradecanoate.....................
The Esterification of tert-Butoxycarbonyl- 
D-leucine with L-p-Nitrobenzyl-B-hydroxy- 
tetradecanoate...............................
ix
Figure 33. The Esterification of tert-Butoxycarbonyl-
L-leucine......................................... 7 8
Figure 34. The Results of Esterification Reactions
Attempted in Isariin Synthetic Studies....... 79
Figure 35. A Presumed Mechanism for the Sodium-
imidazole Catalyzed Esterification............81
Figure 36. The Sodium-imidazole Catalyzed Esteri­
fication of tert-Butoxycarbonyl-D-leucine 82
Figure 37. The Removal of a tert-Butoxycarbonyl Group
Using Boron Trifluoride Diethyletherate.........83
Figure 38. The Elongation of the Depsipeptide Fragment... 85
Figure 39. The Formation of Activated Esters Using
N,N' -Dicyclohexylcarbodiimide................... 87
Figure 40. The Formation of N-Hydroxysuccinimide
Active Esters..................................... 88
Figure 41. The Formation of 1-Hydroxybenzotriazole
Active Esters..................................... 89
Figure 42. The Formation of the L,D,L-Tridepsipeptide....91
Figure 43. The Preparation of o-Nitrophenylsulfenyl-
(8-tert-butyl) aspartate (5_0)...................93
Figure 44. The Preparation of Tetradepsipeptide 5_1........ 95
Figure 45. The Preparation of the Protected Tetra-
peptide Fragment 5j3.............................. 96
Figure 46. The Selective Removal of o-Nitrophenylsulfenyl 
Protecting Groups in the Presence of tert- 
Butyl Esters...................................... 98
Figure 47. Attempted Selective Removal of the o-Nitro­
phenylsulfenyl Group Using HCl in Chloroform..99
Figure 48. Additional Attempts to Remove the o-Nitro-
phenylsulfenyl Group............................ 101
Figure 49. The Preparation of Pentapeptide A ' .............105
Figure 50. The Preparation of Model Octadepsipeptide
65.................................................107
x
Figure 51. The Preparation of the Octadepsipeptide
Precursor to Norsurfactin...................... 108
Figure 52. The Hydrogenolytic Removal of the C- and
N-Terminal Protecting Groups from Octa­
depsipeptide 66_.................................. 109
Figure 53. A General Activated Ester Cyclization
Sequence.......................................... Ill
Figure 54. The Formation of the Protected Cyclo
octadepsipeptide (69 ), Norsurfactin di- 
tert-Butyl Ester.................................114
Figure 55. The Preparation of Norsurfactin (11).......... 115
xi
LIST OF CHARTS
Chart I. A Synthetic Strategy for the Stepwise
Synthesis of Norsurfactin, Variation A ..... 48
Chart II. A Synthetic Strategy for the Stepwise
Synthesis of Norsurfactin, Variation B ..... 69
Chart III. Fragment Synthetic Strategy for
Norsurfactin, Variation A ......................72
Chart IV. Fragment Synthesis of Norsurfactin,






THE SYNTHESIS OF NORSURFACTIN
by
THOMAS L. CIARDELLI
Synthetic strategies are developed for the prepara­
tion of cyclodepsipeptides, particularly those possessing 
amino acid residues with carboxylic acid side chains.
The synthesis of the cyclooctadepsipeptide, nor­
surfactin, is described as an example of the application of 
such strategies.
D-CH-j (CH2) ^ QCHC^CO-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu
I------------------- 0  ----------------------
Norsurfactin
A procedure for the formation of tert-butyl esters 
of 3-hydroxy acids using dimethylformamide dineopentyl 
acetal and tert-butyl alcohol was developed. It was demon­
strated that this procedure is superior to previously 
published methods for the preparation of similar compounds. 
Steric factors influencing depsipeptide bond formation 
between amino acids and 3-hydroxy acid derivatives were
xiii
also investigated.
Improvements in depsipeptide yields using N,N'- 
carbonyldiimidazole were achieved by systematic modifications 




Advancements in the area of peptide synthesis during
the past fifteen years have made the preparation of small
peptides routine and the synthesis of larger peptides and
even small proteins not uncommon. Synthetic procedures for
the preparation of cyclic peptides have also been extensively
investigated, since many are biologically active, functioning
as hormones, fungal toxins, and antibiotics.'*' Procedures
for the preparation of depsipeptides (compounds containing
both amino and hydroxy acid residues linked through amide
and ester bonds) and particularly cyclodepsipeptides, have
not been as extensively investigated. Synthetic studies of
cyclodepsipeptides have been limited almost entirely to the
preparation of compounds containing short, branched-chain
a-hydroxyalkanoic acids as part of the ring system, such as
2-5valmomycin, the enniatms and their analogs. Very little
attention has been focused on depsipeptides containing longer 
chained 8-hydroxyalkanoic acids as part of the ring structure.
Compounds having these structural features include esperin^,
7 8 9 10 11isariin ' , the isarolides , peptidolipids NA ' , serrata-
12 13molide and surfactm. To date, only two among this group,
isariin'*'^ ^  and serratamolide'*'^, have been prepared syn­
thetically.
Serratamolide (Figure 1) is the only member of this 
group with a symmetric, repeating sequence. This structural
1
2feature was exploited in its synthesis by using a unique
17hydroxyacyl insertion reaction. This reaction has no
general applicability in the preparation of the other com­
pounds mentioned.
D-CH-, (CH„) ,CHCH_C0-Ser-0 3 2 6 | 2 |
0*Ser*-C0CH„CH(CH„)cCH.-D 2 2 6 3
Figure 1. Serratamolide,
Isariin (Figure 2) is a cyclohexadepsipeptide having 
a structure more representative of the naturally occurring 




The synthesis of isariin has been accomplished in 
three different ways, including a solid phase procedure.^
It must be noted, however, that the amino acid residues in isar­
iin have no side chain functionality. This fact greatly 
simplifies the synthesis. Although the techniques used in 
the preparation of isariin could be of general utility in 
the preparation of similar compounds, they are not by them-
3selves sufficient, since esperin, peptiodolipids NA and 
surfactin all contain amino acid residues with third func­
tionality.
There is a need for the development and elaboration 
of synthetic procedures that are applicable to several 
classes of cyclodepsipeptides. There is, in fact, a need 
for a variety of successful procedures, since it has already 
been firmly established in other areas of peptide synthesis 
that an extremely successful technique for one compound 
might fail when dealing with compounds of very similar 
structure.
In order to investigate and develope synthetic 
techniques having a broader scope than have been previously 
reported, syntheses of surfactin, esperin and related cyclo­
depsipeptides were chosen as long term objectives.
Surfactin (Figure 3) is a cyclooctadepsipeptide 




Figure 3. Surfactin (Bacillus subtilis).
4Esperin (Figure 4) is also a cyclooctadepsipeptide 
to which a very similar (but in some respects equivocal) 
structure has been assigned.
RCHCH2CO-Glu-?-Leu-?-Leu-Val-Asp-?-Leu-?-Leu(Val)-OH 
  0 --------------
R = n_C12H25" (45%)
R = n-CllH23~ (35%)
R = n-C10H2l" (20%)
Val C-terminal replacement M30%)
Figure 4. The Structure of Esperin (Bacillus mesentericus).
The configurations of the leucine residues are open 
to question. It is known, however, with reasonable certainty 
that the D-leucine to L-leucine ratio is one.
The structural similarities and uncertainties of 
these two compounds, the presence of side chain functionality 
and their remarkable biological activity make the synthesis 
of surfactin and esperin an interesting and potentially 
useful challenge. The development and elaboration of syn­
thetic procedures useful for the preparation of surfactin, 




The production of hemolytic factors in the culture
medium of certain aerobic sporogenic bacilli was first re-
18 19ported in the 1950's. ' However, it was not until 1970
that Bernheimer and Avigad isolated from B. subtilis a
2 0hemolytic compound which they called subtilysin. Earlier,
however, Arima and coworkers had isolated and characterized
a compound (which they called surfactin) having anticoagu-
lent and antibiotic activity from the culture medium of B. 
21-27subtilis. Subtilysin and surfactin proved to have
identical structures (1).
(CH3)2CH(CH2)9CHCH2CO-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu-
   0 --------------------
1
Surfactin was isolated from supernatant culture
fluids of Bacillus subtilis IAM 1213 by straightforward
25chemical procedures. The precipitate obtained from acid­
ification of the culture filtrate was converted to a calcium 
salt. Reacidification gave crude surfactin which was further 
purified by chromatography on Sephadex G-50 and Sephadex LH- 
20. Crystalline surfactin was isolated from 50% aqueous 
acetone after a two month cooling period. A yield of 40-50 
mg per liter of culture medium was reported. Surfactin was
6obtained as a white crystalline solid, mp 138-140°, [ct] D 
+40° (c 1, CHC13) and [ct] D -39° (c 1, CH3OH) .
Surfactin has been shown to be a strong surface
active agent, decreasing the surface tension of dilute basic
solutions more than twice as much as equivalent concentra-
22tions of sodium lauryl sulfate. It is the first compound 
possessing such strong surface activity to be isolated from 
microbial origins. High surface activity can be attributed 
to the ambiphilic nature of the surfactin structure. The 
extended hydrocarbon chain of the g-hydroxy acid residue and 
the alkyl side chains of the leucine and valine residues 
comprise a lipophilic ensemble while the depsipeptide ring 
and particularly the easily ionizable side chain carboxylic 
acid moieties of aspartic and glutamic acids are hydrophilic. 
The surface activity arising from these structural features 
is more than just an interesting physical property, it is 
very likely that it contributes to surfactin's unique spec­
trum of biological activity as well.
Buffered solutions of surfactin were found to be 
20strongly hemolytic. Red cells from a variety of animals 
were lyzed, but the greatest activity was shown toward 
erythrocytes from rabbit, man and guinea pig. The presence 
of divalent cations in the test medium increased the rate of 
lysis as did rapid chilling. Surfactin's hemolytic activity 
was found to be inhibited by serum and low concentrations of 
several phosphatides.
7As is typical of many cyclic peptides and depsipep­
tides, surfactin possesses antimicrobial and bactereolytic 
20 25 27activity. ' ' The growth of Streptococcus pyogenes, Caryne
diptheriae, and Bacillus megaterium were completely inhibited 
at dilutions of less than 2 0 yg/ml and Sarcina lutea and 
Micrococcus lysodeikicus were partially inhibited at dilutions 
of 150 yg/ml. Surfactin also displayed lytic activity toward 
protoplasts and spheroplasts of several Gram-positive bacteria 
but only one Gram-negative organism (Escherichia coli).
The hemolytic, antimicrobial and bacteriolytic proper­
ties of surfactin all in some way result from its ambiphilic
structure. Other detergent materials have been found to
25have related properties. It has been shown that surfactin 
has a greater affinity for the lipid portion of the cell
membrane than for the protein portion. A direct interaction
. . 27with membrane phospholipids has also been established.
Surfactin is known to inhibit other membrane centered pro­
cesses, such as the utilization of glucose and the synthesis
25(But not the activity) of alkaline phosphatase. These
data suggest that the ambiphilic nature of surfactin allows 
sufficient solubility in the lipid portion of the membrane 
so that it can disrupt membrane processes causing a loss
of osmotic balance and ultimately cell lysis.
It was anticoagulant activity, not antimicrobial 
activity that initiated the research which ultimately led 
to the isolation of surfactin. While searching for substances 
that would prevent fibrin clot dissolution, Kakinuma and
8coworkers determined that the culture broths of several
strains of B. subtilis greatly promoted plasmin-catalyzed
21fibrin deterioration. Initial tests suggested that the 
anticoagulant activity of surfactin was due to its ability 
to extend the range of plasmin (a proteolytic fibrin digest­
ing enzyme). It was speculated that surfactin somehow al­
tered the enzyme substrate environment so as to facilitate 
the activity of the enzyme. However, in more detailed 
investigations involving an in vitro thrombin-fibrinogen 
system* (no plasmin present) it was found that a 50% inhi­
bition of thrombin activity occurred at surfactin concen­
trations of 30 lag/ml. Interestingly, it was found that the 
proteolytic activity of the enzyme, thrombin, toward fibrin­
ogen leading to the formation of fibrin monomer was not 
inhibited by surfactin. Sedimentation studies on thrombin- 
fibrinogen-surfactin systems showed the disappearance of 
fibrinogen and the appearance of fibrin oligomer but no 
fibrin polymer or clot. The site of inhibition by surfactin 
in the clotting system was therefore determined to be the 
polymerization of fibrin monomer to fibrin polymer. It was 
proposed that the surfactant nature of the compound enabled
*A simplified scheme of the blood clotting system can be 




— Fibrin Clot < -------- Fibrin Polymer
Plasmin (fibrinolysin)
----------------------------------- >  Fibrin Breakdown
Products
9it to solubilize fibrin oligomers thus preventing further
polymerization and precipitation of the fibrin clot. Other
detergents are known to dissaggregate and solubilize fibrin 
2 8polymer. Surfactin is unique in its anticoagulant activity
since other anticoagulants, such as the coumarins or
heparin, possess little or no in vitro activity.*
To date there have been no in vivo studies of sur-
factin's anticoagulant activity. However surfactin has shown
a different kind of activity when administered orally to
test animals. When surfactin was fed to rats and chickens,
a significant lowering of cholesterol levels occurred in
29both the plasma and liver. Cholesterol levels were 
lowered by approximately 30% in rats and 50% in chickens 
when compared to control animals on high cholesterol diets. 
The activity was found to be specific for cholesterol as 
the levels of other lipids remained unchanged. This hypo- 
cholesterolemic effect was manifested by a 0.3% diet sup­
plement.
More detailed studies showed surfactin inhibited
3
the absorbtion of cholesterol- H, however, in contrast to
the behavior of 8-sitosterol (a naturally occurring inhib-
29itor of cholesterol absorbtion ) no stoichiometric binding
14with cholesterol- C could be observed. Furthermore,
*For a discussion of other compounds having anticoagulant 
activity see reference 46a.
10
14studies with surfactin- C revealed that there was no ab­
sorbtion of surfactin in the gastrointestinal tract. In-
14gested surfactin- C was completely excreted in the feces. 
These facts along with the correlation between the critical 
micelle concentration of surfactin (5-10 yg/ml) and the fact 
that, in vitro, surfactin-cholesterol interactions begin at 
surfactin concentrations of 2-20 yg/ml regardless of choles­
terol concentration, suggest that the hypocholesterolemic 
activity of surfactin is a result of physico-chemical inter­
actions. It is likely that the surface active nature of 
surfactin causes the formation of micelles which selectively 
include cholesterol and allow it to pass unabsorbed through 
the gastrointestinal tract.
In summary, in every case of reported biological 
activity for surfactin there seems to be a direct link to 
its surface activity. No other surface active agent has 
been found to possess such a remarkable range of biological 
activity. This makes the elucidation of structure-activity 
relationships a complex but potentially significant problem.
The structure of surfactin has been firmly established. 
Analytical data indicates that the crystalline material 
isolated from the culture broths of B. subtilis is composed 
of at least 90% of a material having structure (1).
Acid hydrolysis of the crystalline material re­
sulted in a two phase product. A hydrochloric acid-soluble 
portion composed of amino acids and an oily, hydrochloric 
acid-insoluble, portion composed of fatty acids and un-
11
hydrolyzed surfactin. These results indicated that sur­
factin was a peptidolipid.
The amino acid sequence of the peptide portion
23of the molecule was determined by classical techniques. 
Surfactin was subjected to partial acid hydrolysis and the 
resulting peptide fragments were separated chromatographic- 
ally. The amino acid sequences of each of the thirteen
30peptides obtained were determined using the Edman technique. 
From sequence overlap data the structure of the linear 
peptide fragment of surfactin was established as 2^ .
Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu*
2
The positions of the D-leucine residues were deter­
mined by subjecting the peptide fragments obtained from 
hydrolysis to the action of D-amino acid oxidase. Amino 
acid composition was determined before and after enzymatic 
digestion. Only the peptide fragments containing a D-leucine 
residue showed the loss of a leucine residue in the amino 
acid composition after the enzyme treatment. Comparing these 
results with the previously determined fragment sequence 
data, the positions of the D-leucine residues were located 
unambiguously.
*It should be noted that a small amount of L-isoleucine was 
also detected indicating minor variations in the peptide 
sequence.
12
The determination of the structure of the fatty acid
2 1component of surfactin was accomplished as follows. Sub­
jecting crystalline surfactin to methanolysis produced an 
oily material which was chromatographed on silica gel to 
give two fractions. The first fraction was composed of a 
fatty acid methyl ester shown to be greater than 90% pure 
by GLC. This fatty acid ester was shown to be 13-methyl-
3-hydroxytetradecanoic acid methyl ester (3j based on 
elemental analysis, the infrared spectrum, the nuclear 
magnetic resonance spectrum and mass spectral evidence.
Minor impurities detected during GLC analysis were shown 
to be esters of C^3 and 3-hydroxy acids. These esters
represented less than 10% of the methanolysis product.
(c h 3)2c h (c h 2 )9c h c h 2c o 2c h 3
OH
Using the same analytical techniques, a compound 
found in the second chromatographic fraction was determined 
to be the dimethyl N-acyl glutamate 4^ , confirming that 
glutamic acid is the N-terminal amino acid residue of the 
peptide. Thus the entire acyclic structure of surfactin 
was established as 5 .
13
CH_CH0CO_CH- | 2 2 2 3




It was determined that although surfactin itself was 
not acylated by treatment with pyridine-acetic anhydride, a 
compound obtained by mild alkaline hydrolysis of surfactin 
was easily acylated under these conditions. This suggested 
that in surfactin the hydroxyl group of the 3-hydroxy fatty 
acid was involved in a lactone bond.
Which of the three available carboxyl groups in the 
peptide residue formed the lactone bond was determined as 
follows. When surfactin was subjected to reduction by 
LiBH^ (only ester bonds being reduced) the amino acid com­
position of the reduction product indicated the loss of one
31leucine residue. If surfactin was first treated with diazo- 
methane and then reduced with LiBH^, aspartic acid, glutamic 
acid and one of the four leucine residues disappeared. When 
the lactone ring of surfactin was opened prior to reduction 
by mild alkaline hydrolysis, no change in amino acid com­
position was observed. These results located the lactone 
bond between the hydroxyl group of the fatty acid and the
14
carboxyl group of the C-terminal leucine. Disregarding 
minor variants, the total structure of surfactin was there­
fore shown to be 1 .
This structure was later confirmed by mass spec-
32 33 34trometry using the techniques of Lederer and Thomas.
It should be noted that the possibility exists that 
the structure of the active substance in the culture broth 
might be slightly different than that of the crystalline 
material. The opening and rearrangement of the lactone bond 
during isolation and purification could have occurred, how­
ever, the high biological activity of the crystalline 
material makes this unlikely.
Esperin
Isolation of the substance, esperin, from strains of
35 36B. mesentericus was first reported in the early 1950's. '
The substance was found to have a very high degree of anti­
biotic activity toward Mycobacterium tuberculosis.
Available data concerning esperin is far less 
reliable and precise than that for surfactin. Most of the 
published reports on esperin are filled with ambiguities, 
equivocal interpretations of data, and consequently struc­
tural assignments that are tenuous. There is even doubt
concerning the authenticity of the producing bacterial strain,
45Bacillus mesentericus. There is, however, sufficient 
evidence available to indicate that surfactin and esperin 
are structurally similar. Whether the similarities in 
structure also manifest themselves as similarities in bio-
15
logical activity has yet to be fully elucidated.
The isolation of esperin was accomplished by acid­
ification of the culture broths of B. mesentericus followed 
by reprecipitation of the resulting solid from methanol-water 
and acetone-petroleum ether. A solid substance was obtained 
with a melting point of 235°. The substance inhibited the 
growth of M. tuberculosis at a dilution of 1:500,000.
It was found that alkaline hydrolysis of esperin 
followed by acidification yielded a different substance, 
esperinic acid (mp 105°) which inhibited the growth of M. 
tuberculosis at dilutions of 1:160,000. This is the only 
biological activity reported for either material.
Attempted structural elucidations for esperin and 
esperinic acid have been plagued with incorrect assignments. 
The exact structure of these compounds has yet to be unam­
biguously determined.
The results of the first structural studies were
37based on analyses of acid hydrolysates. The ether extracts
of these hydrolysates were found to contain a material which
appeared to be a fatty acid having fourteen to sixteen carbon
atoms. The ether insoluble portion contained the amino
acids; D,L-leucine, L-aspartic acid and L-valine. The
presence of glutamic acid was not reported. More detailed
investigation identified the fatty acid as trans-2-tride-
3 8cenoic acid, (6J . No higher or lower homologs of this 
acid were reported.
It was not until seven years later that the same
authors published additional structural data causing a re-
38a.vision of prior interpretations. Esperin was reported
to be a crystalline material (mp 238°) having a molecular 
weight of 730-800, an optical rotation of -24° (0.66% in 
methanol) with empirical formula, C 3 9 H 6 9 N 5 ° n  • Analyses 
of the acid hydrolysates reportedly showed L-glutamic acid 
as well as L-aspartic acid, L-leucine, D-leucine and L- 
valine. As before, 2-tridecenoic acid was recovered from 
the ether soluble portion of the hydrolysates, however, the 
presence of unsaturation was attributed to the acid cata­
lyzed dehydration of $-hydroxytridecanoic acid (2), the 
actual fatty acid presumed to be in esperin. The config­
uration at the asymmetric carbon of the hydroxy acid, along 




Based on the results of complete and partial acid 
hydrolysis, spectral data and a carboxypeptidase C-terminal 
amino acid determination (the significance of which will be 
discussed later), the structure of espernic acid (produced 
by mild alkaline hydrolysis of esperin) was proposed as £ .
L or D-CH3 (CH2)9CHCH2CO-Glu-Asp-Val-Leu-D-Leu-OH
OH
8
Successive hydrazinolysis, Curtius rearrangement and 
hydrolysis of esperin transformed the aspartic acid residue 
to a ,8-diaminopropionic acid indicating that the 8-carboxyl 
group of the aspartic acid residue participated in the lac­
tone bond. Based on these data the structure of esperin was 
proposed as 9^ .
L or D-CH3 (CH2)9CHCH2CO-Glu-Asp-Val-Leu-D-Leu-OH
I o  1
9
Citing reasons such as "some of the data of the 
Japanese authors did not seem very reliable" and "compounds 
of such unusual structure containing a cyclotridepsipeptide 
system have not been met previously in nature", a Soviet 
group decided to test the validity of structures 8^ and 9_ 
by total synthesis. In two separate and unambiguous syn­
18
theses, compounds having structures 8 and 9 were pre­
pared. Separate diastereomeric compounds containing both 
D- and L-8-hydroxytridecanoic acid residues were prepared 
in the case of £ , however in the preparation of 9^ only 
the synthetic intermediate containing the L-8-hydroxy acid 
could be converted to the cyclic product. All of the com­
pounds synthesized were totally void of antibiotic activity 
and their physical properties were completely different from 
those of the natural substances. The proposed structures of 
esperin (9) and esperinic acid (8) were therefore shown 
to be incorrect.
Faced with this new evidence, the original investi­
gators undertook a new structural investigation.^ Collab­
orating with D. W. Thomas and using his newly developed
technique involving mass spectrometry of permethylated
34peptide derivatives , some of the ambiguities concerning 
the structure of esperin were clarified. From the mass 
spectral data it was determined that the fatty acid formation 
in the acid hydrolysates was a mixture of components and not 
a single compound. The presence of 2-tridecenoic acid along 
with its and C^ ,- homologs now indicated the following
three 8-hydroxy acids were present in esperin in the per­
centages indicated in Figure 5. It should be noted that 
8-hydroxytridecanoic acid (1) was the only previously 






c h 3 (c h 2 ) 1;lc h c h 2c o 2h
I
(45%)
Figure 5. The 3-Hydroxy Fatty Acids Present in Esperin.
amino acid sequence. It was determined that esperin con­
tained, not a pentapeptide residue as previously thought, 
but the heptapeptide 10 . However, the peptide portion of 
esperin was not homogeneous; L-valine appeared as a C- 
terminal variant in approximately 3 0% abundance. Mass 
spectral data could not provide any information about the 
configuration of the amino and hydroxy acid residues.




Based on all the available data the structure of the 
esperin complex may be represented as shown in Figure 4. It 
is evident that several uncertainties remain in the struc­
ture of esperin. Of major concern are the configurations 
of the leucine residues. It is known that there are two D- 
and two L-leucine residues in the molecule, however, which 
residue is of which configuration is unknown. It should be 
recalled that in the original incorrect structure £ the 
C-terminal leucine was assigned the D-configuration while 
the penultimate leucine residue was determined to be L.
The assignments were based on the fact that when esperin and 
esperinic acid were subjected to carboxypeptidase (an en­
zyme which successively hydrolyzes L-amino acids from the 
C-terminal end of peptides and proteins) no hydrolysis took 
place. The investigators concluded from this that the C- 
terminal leucyl residue was of the D-configuration (there­
fore blocking enzymatic degradation). The presence of a 
D-leucine at the C-terminal end of the peptide would be 
expected to inhibit carboxypeptidase hydrolysis, however, 
the fact that no hydrolysis occurred is insufficient evidence 
to warrant the assignment of the D-configuration. It has 
been shown that in the case of an N-acyl dipeptide, the 
presence of a D-amino acid in the penultimate position
greatly inhibited the carboxypeptidase hydrolysis of a C-
42terminal L-residue. In another case concerning the 
structural determination of isariin (Figure 2), a proposed 
structure based on the assumption that carboxypeptidase
21
inhibition was caused by the presence of a D-amino acid
14 43was proven incorrect. ' Chemical synthesis verified a 
correct structure based on the assumption that a penultimate 
D-amino acid inhibited the enzyme. Clearly then, the assign­
ment of the D-conf iguration to the C-terminal residue of 
is not warranted. Since inhibition of carboxypeptidase could 
be expected if the penultimate leucine residue was of the 
D-configuration and the C-terminal leucine residue was of 
the L-configuration (it should be noted that this is the 
same sequence that appears in the last two C-terminal resi­
dues of surfactin, Figure 3).
The assignment of the D-configuration to the C- 
terminal leucine looks even more doubtful when one considers 
that only L-valine (no D-valine) was found to be present in 
the acid hydrolysates, where as, both D- and L-leucine were 
identified. Considering the fact that valine apparently 
appears as a C-terminal variant in 30% abundance, it seems 
unlikely that L-valine would replace D-leucine in a compound 
derived from an enzyme mediated biosynthesis. Seemingly 
the only valid conclusion that can be drawn from the carboxy­
peptidase data is that at least one of the leucine residues 
in the C-terminal leucylleucine couplet is of the D-configur- 
ation. There is no information available concerning the 
configurations of the internal leucine residues. All of the
questionable configurations could be determined by the D-
22a m m o  acid oxidase technique used in surfactin.
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The configurations of the 3-hydroxy acid residues 
have also not been determined. It should be noted, however, 
that the 3 -hydroxy acid components of isariin, peptidolipids
NA, serratamolide, surfactin and the related peptolide,
46viscosin have all been shown to have the D-configuration.
Another uncertainty in the structure concerns the 
C-terminal valine variant. Does valine appear in equal 
abundance with each fatty acid homolog or does it occur ex­
clusively with only one or two of the fatty acids? In the 
case of the peptidolipids NA, it was shown that the single 
variant residue occurred in the presence of only one of the 
three homologous 3 -hydroxy fatty acids.
Although there are many uncertainties surrounding 
the structure of the esperin complex it is evident that 
esperin and surfactin are structurally very similar. They 
may, in fact, have identical peptide sequences. The 3- 
hydroxy fatty acid portion of the compounds are undeniably 
different, surfactin being composed primarily of an iso­
fatty acid while the esperin complex is composed of a 
homologous series of normal fatty acids. The positions of 
the lactone bonds in the isolated crystalline materials are 
also different. However, since the isolation procedures 
for both substances differ, a rearrangement of the lactone 
bond in one or both compounds during workup, albeit unlikely, 
cannot be ruled out.
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The true similarities between the two substances 
will not be known until the structure of esperin is 
completely elucidated. The esperin complex should be 
resolved into its components, possibly using high pressure 
liquid chromatography, and the structure of each component 
should be analyzed with emphasis on fatty acid composition, 
sequence and configuration of amino acids and variation of 
C-terminal residues. However, unavailability of the produc­
ing strain, B. mesentericus, makes this type of analysis 
impossible. Alternatively, compounds having the most 
probable structures could be synthesized and their physical 
and biological properties compared with those reported for 
the natural materials. Once the structure of the experin 
complex is determined, a comparison of the full spectrum 
of biological activity of both esperin and surfactin could 
provide information concerning structure-activity relation­
ships for both compounds.
When examining both esperin and surfactin as 
potential target compounds in the development of synthetic 
techniques, obvious difficulties appear even before specific 
synthetic strategies are considered. In the case of the 
esperins, the uncertainties in structure demand that a 
number of variants be synthesized. A synthetic problem of 
this magnitude could be more easily dealt with when suit­
able synthetic techniques for the rapid preparation of 
compounds in this class of cyclodepsipeptides have been 
developed.
24
Surfactin is a more appropriate compound for initial 
study. Its structure is unambiguous and its variety of bio­
logical activity should make verification of a synthetic 
sample relatively easy. The greater availability of natural 
surfactin for comparative purposes also must be considered. 
However, the presence of an iso-g-hydroxy fatty acid in the 
structure of surfactin presents additional complications in 
the synthesis. Before dealing with the synthesis of the 
depsipeptide portion of the structure, the preparation of 
optically pure D-13-methyl-g-hydroxytetradecanoic acid would 
have to be accomplished. Although several acceptable routes
to 6 -hydroxy acids are available, including a procedure that
44leads directly to optically active compounds , suitable 
synthetic precursors to D-13-methyl-6-hydroxytetradecanoic 
acid are not available and would themselves have to be pre­
pared. The preparation of sufficient quantities of D-13- 
methyl-6 -hydroxytetradecanoic acid to begin the synthesis, 
if not difficult, would at least be time consuming.
In order to avoid this added complication and focus 
directly on the preparation of the depsipeptide portion 
of the molecule, a compound having structure 1_1 , labeled 
norsurfactin, was chosen as the initial synthetic objective.




The only structural difference between this compound and 
surfactin is the absence of the iso-methyl group on 
Suitable precursors to this normal 3-hydroxy acid, D-3- 
hydroxytetradecanoic acid (1 2 ), are commercially available 
and the time required to prepare sufficient quantities of 
optically pure material should be greatly reduced.
d-ch3 (ch2 )1 q^hch 2 co2h
12
It is not unreasonable to assume that the absence 
of the methyl group would have little affect on the biolog­
ical properties of surfactin. There is no loss or change 
of chirality involved and the biological activities of 
surfactin seem to be a result of its surface activity which 
also should not be greatly affected by such a change.
Techniques developed in a successful preparation of 
norsurfactin could be used both directly in the preparation 
of surfactin (when sufficient iso-3 -hydroxy acid is avail­




The direction of a synthetic strategy leading to the 
preparation of norsurfactin (1 1 .) is necessarily determined 
by the nature of the cyclization step. There are two possible 
options; the formation of the depsipeptide ring via a cycli­
zation forming the single lactone bond, or the formation of 
the depsipeptide ring via a cyclization forming one of the 
seven peptide bonds. Both techniques have advantages and 
disadvantages.
The preparation of cyclodepsipeptides by cyclizations 
through lactone bonds has been reported. Several syntheses
of the actinomycins and their analogs have been carried out
47-50using this technique. Implementation of a lactonization
cyclization strategy for norsurfactin would require the 
preparation of the acyclic peptidolipid intermediate 13.
OP 1 OP 1
I
D-CH3 (CH2 )1 0 CHCH2 CO-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu-OP 
OH
P,P' = carboxylic acid protecting groups
1 2
The synthesis of this intermediate could be carried 
out using straightforward peptide coupling techniques.^ 
Protecting groups for the side chain carboxylic acid moieties 
of aspartic and glutamic acid and the C-terminal leucine
27
residue would have to be carefully chosen, however, the 
protecting group on leucine (P) must be able to be removed 
selectively, leaving the protecting groups on the aspartic 
and glutamic residues (P') intact. The P' groups can be 
removed only after the cyclization has been completed. Base 
sensitive protecting groups (e.g., methyl or ethyl esters) 
could not be chosen for P' since subjecting the cyclized 
product to an alkaline medium required for their removal 
would certainly cleave the lactone bond. The choice of 
both carboxylic acid protecting groups would have to be co­
ordinated with the selection of N-terminal amino protecting 
groups to be used in a fragment or stepwise build up of the 
peptide chain. Although the hydroxyl group of the 3-hydroxy
acid residue would not have to be protected if suitable
39coupling reagents were used , it is evident that the choice
of the other protecting groups mentioned would have to be
considered carefully.
Synthesis of acyclic intermediates similar to L3
have been reported in the literature, but usually only as
part of a short-cut method of structure proof. In studies
40of synthetic approaches to derivatives of esperin and 
43isariin , completely deprotected, acyclic 3 -hydroxy acyl 
peptides somewhat similar to 13^  have been prepared. The 
same derivatives could, in principle, be obtained from the 
natural cyclodepsipeptides by mild alkaline hydrolysis 
provided correct structural assignments have been made. 
Comparison of the synthetic compounds with hydrolytic pro­
28
ducts from the natural material short-circuited the need 
for a total synthesis of the complete cyclodepsipeptides.
The previously proposed structure of esperin was thus shown 
to be incorrect and a suspected structure for isariin was 
confirmed.
A structure proof is not of primary importance in 
this study. The structure of surfactin is based on rela­
tively firm evidence. In addition, the fact that there is 
a structural difference (albeit a very minor one) between 
norsurfactin and natural surfactin would, nevertheless, make 
the validity of a comparison between synthetic and naturally 
derived intermediates questionable.
Other disadvantages in a strategy based on the prep­
aration of the intermediate 1J3 become obvious when one more 
closely examines the literature on lactone bond cyclizations. 
A carboxyl group usually requires a much higher degree of 
activation for the formation of ester or lactone bonds than
it does for the formation of amide or lactam bonds. Gener-
52 41ally acxd chlorides , benzenesulfonic anhydrides or highly
49 53activated esters ' are used to form depsipeptide ester
bonds. If such techniques were to be used to lactonize 13,
the risk of racemization of the activated C-terminal leucine
residue would be great. Also there are reports that even
the aforementioned, and several other, highly activating
techniques have failed to promote the formation of lactone
54-56cyclodepsipeptide bonds. Particularly pertinent is a
report on the attempted synthesis of isariin (Figure 2).
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The cyclization of an intermediate similar to 1_3 was attempted 
via the formation of a lactone bond (Figure 6 ). None of the 
desired cyclized product, isariin, could be detected as a 
result of using any of the procedures listed in Figure 6 , even
when high pressure liquid chromatography was used to analyze
the reaction mixtures. On the basis of these reports, a 
lactonization strategy for the preparation of norsurfactin 
would not appear to be a promising approach.
The closure of the depsipeptide ring of norsurfactin
via formation of one of the amide bonds is the alternate 
choice. Even at first glance, the availability of a greater 
variety of proven peptide bond forming techniques tends to 
make this route appear more attractive than lactonization.
In principle, the cyclization coupling step could be accom­
plished at any of the seven amide bonds in norsurfactin. 
However, even though a lesser degree of carboxyl activation 
is needed for amide bond formation, racemization can occur
with all activation procedures and is of constant concern to
62 62apeptide chemists. ' It becomes even more significant in
cyclizations since the activated carboxyl group is usually 
present in solution for longer periods of time than in 
routine peptide couplings. It survives longer because of 
the conditions used to maximize the yield of cyclic product. 
The longer the activated group remains in solution the greater 
the chance of racemization of the C-terminal residue.
30
C-terminalD-CH- (CH9) oCHCHoC0-Gly-Val-D-Leu-Ala-Val-0H - --3 2. 87 2 J activation
q h (methods A-G)
Isariic Acid
D-CH3 (CH2 )8 CHCH2 CO-Gly-Val-D-Leu-Ala-Valu n u n - ^ u - v j j L y - v a i - u - i i e u - A i a - v a i - i
LJ o ]
Isariin
r = \  4 9
A. CHgCOCl/ jj NH  ^  no product isolated
B. S0C12 5 3   >
57C. N ,N '-dicyclohexylcarbodiimide ---- "
D. N,N'-carbonyldiimidazole3  ^ ---"
59E. Dimethylformamide-  >  "
dineopentyl acetal





Figure 6 . Attempts to Lactonize Isariic Acid
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Another consideration in designing an amide bond 
cyclization strategy is the steric hindrance encountered 
between the two residues involved in the ring-forming step. 
One would expect lower yields when residues with bulky side 
chains (e.g., leucine or valine) are involved.
Considering the above facts, there is a single most 
favorable position for the site of amide bond formation lead­
ing to cyclic product. A cyclization between the carboxyl 
group of the D-3-hydroxytetradecanoic acid residue and the 
amino group of the glutamic acid residue becomes the logical 
choice. This strategy would require the preparation of the 
acyclic intermediate 14.
OP ' OP '
I
D-CH 3 (CH2) 1 0 CHCH2 CO 2 Pc P^j-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu-i
I---------------------- 0 ------------------------------
14
Pc , Pc ' = carboxylic acid protecting groups.
PN = amino protecting groups.
By attempting a cyclization between the 3-hydroxy 
acid and glutamic acid residues, the risk of racemization is 
greatly diminished. The center of chirality in the 3-hydroxy 
acid residue is 3 to the activated carboxyl group and would 
not be expected to undergo racemization. Steric hindrance 
should also be less of a problem since there would be no 
alkyl side chain a to the activated carboxyl group.
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The preparation of intermediate r3 could be developed 
along one of two routes. The heptapeptide chain with pro­
tected third functions and N-terminal group could be prepared 
and then esterification of the C-terminal leucine would give 
product L4 (Figure 7). Alternatively the ester bond could 
be formed first between the carboxyl protected D-p-hydroxy- 
tetradecanoic acid derivative and a suitably protected leucine 
derivative. The peptide chain could then be lengthened by 
stepwise addition of amino acid derivatives, or by fragment 
coupling to produce 14_ (Figure 8 ).
In at least one case the former procedure (Figure 7)
15gave unsatisfactory results (very low yields for the pep­
tide esterification step) while there have been several
reports of satisfactory results in similar systems using the
14-16 41second approach (Figure 8 ). ' Therefore, the develop­
ment of a synthetic strategy for norsurfactin based on the 
preparation of intermediate 14^  as shown in Figure 8 was 
judged to be the more attractive alternative.
Many methods have been developed for the protection 
of amino, carboxylic acid and other functional groups in 
peptides and amino acids. However, the requirements imposed 
by the structure of intermediate 14^  and a strategy such as 
outlined in Figure 8 greatly restrict the protecting groups. 
Since the ester bond is to be formed initially, any protect­
ing groups requiring alkaline conditions for removal are 
eliminated. The groups protecting the carboxylic acid moiety 
of the 8 -hydroxy acid (Pc in Figure 8 ) and the groups protect-
PC' PC' = carboxylic acid protecting groups 
PN = amino protecting groups
Figure 7. Thje Preparation of Intermediate 1£ via Esterif ication of the
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D-CH 3 (CH2 )1 ()CHCH2 C0 2 Pc + PN-Leu-OH ---- >
Ah
D-CH3 (CH2 )1 0 CHCH 2 CO 2 Pc PN-Leu-
----------- o --------
°V OPc '
D-CH-,(CH~)n _CHCH»CO_P_ P '-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu 3 2 10 i 2 2 C N
 0 ----------------------- ]
Pc , Pc ' = carboxylic acid protecting groups. 
PN' PN ' = am -^no Protecting groups.
Figure 8 . The Preparation of Intermediate 1£ by Initial 
Formation of the Ester Bond Followed by 
Lengthening of the Peptide Chain.
ing the side chain carboxylic acid moieties of the aspartic 
and glutamic acid residues (Pc ' in Figure 8 ) must be stable 
to conditions that will remove the N-terminal protecting 
groups used during the build up of the peptide. The Pc ' 
protecting groups must also be stable to the removal condi­
tions of both the Pc and PN ' protecting groups that must be 
removed prior to cyclization.
There is a greater flexibility in the choice of 
methods for the protection of the N-terminal positions of 
the C-terminal leucine residues encountered in the first two 
steps of the peptide chain elaboration sequence. The essen­
tial limitation to be considered for these residues is that 
the group used (PN ) must be removable under conditions that 
will leave the P^ group intact (Figure 9). However, when the 
protected aspartic acid residue is incorporated into the 
depsipeptide chain, the requirements for N-terminal protec­
tion are more restrictive. For example, the N-terminal 
protecting group on the aspartic acid residue (and on all 
subsequent residues) must be removable under conditions that 
will leave both the Pc and P^ ,' groups intact (Figure 10).
A final consideration is that the protecting groups 
on the third functions of the aspartic and glutamic acids 
must withstand the cyclization step and be removable under 
conditions that won't effect the peptide or lactone bonds 
in the cyclized product.
Keeping in mind all of these limitations, a specific 
synthetic strategy based on the one outlined in Figure 8 
may be formulated.
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D-CH3 (CH2 ) 1 ()CHCH2 C0 2 Pc PN-D-Leu-Leu]0
D-CH3 (CH2 )1 0 CHCH2 CO2 Pc H-D-Leu-Leu
1------------ o -------------]
Figure 9. The Removal of the N-terminal Protecting Group 




D-CH3 (CH2 ) 1 0 CHCH 2 CO 2 Pc H-Asp-D-Leu-Leu-J
I-------------- o --------------- 1
Figure 10. Removal of the N-terminal Protecting Group from 
Aspartic Acid.
?PC'
D-CH 3 (CH2 )1 0 CHCH2 CO 2 Pc Pn 1-Asp-D-Leu-Leu
1------------- o --------------------
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Of the numerous methods reported for the protection of 
carboxylic acid groups in amino acids and peptides, esterifi-
/T A /rc
cation has proven to be the most useful. ' The use of 
methyl or ethyl esters in the norsurfactin synthesis is 
eliminated because the alkaline conditions needed for their 
removal would affect the latent lactone bond. However, tert- 
butyl, benzyl and substituted benzyl esters are alternative 
carboxyl acid protecting groups. Conditions used for their 
removal are mild and non-alkaline making them suitable for 
the synthesis of norsurfactin.
The utility of tert-butyl esters (OBu^) for peptide
6 6 6 7synthesis was first demonstrated by Anderson and Trachner.
tert-Butyl esters of amino acids are easily prepared by an
acid catalyzed reaction with isobutylene. The esters thus
formed are stable to alkaline and hydrogenolytic conditions
but may be easily removed under mildly acidic conditions
that will not affect peptide bonds or most other protecting
groups.
The benzyl ester (OBzl) was first introduced to pep-
6 8tide chemistry by Bergmann. Benzyl esters of amino acids 
and peptides are typically prepared by acid catalyzed ester- 
ification using benzyl alcohol. The most convenient method 
for their removal is catalytic hydrogenation, although, 
benzyl esters may be removed under acidic and alkaline con­
ditions also. They are, however, stable to the mildly acidic 
conditions needed to remove tert-butyl esters.
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Both benzyl and tert-butyl esters could be used in 
this synthesis. If, for example, in the case of intermediate 
14, group Pc were a tert-butyl ester and the Pc 1 groups were 
benzyl esters (14a) then the criteria established for car- 
boxylic acid protecting groups would be satisfied. The tert- 
butyl ester on the 6 -hydroxy acid residue could be removed 
with mild acid leaving both benzyl esters intact. After 
cyclization the benzyl esters could be removed hydrogenolyt- 
ically without disturbing either the lactone or peptide bonds.
OBzl OBzl
D-CH3 (CH2 )1 0 CHCH 2 CO 2 But PN-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu-.
I---------------------- o ----------------------------- 10
14a
Having justified the selection of suitable carboxylic 
acid protecting groups, attention can now be focused on N- 
terminal amino protecting groups. Protection of the amino 
groups on the amino acid and peptide derivatives required 
for the synthesis must be compatable with the methods chosen 
for carboxylic acid protection and with the coupling proce­
dures used.
Methods for the protection of amino groups in peptide 
synthesis are even more numerous than those available for 
carboxylic acid p r o t e c t i o n . ^ ^  By far the most useful and 
most important class of N-terminal protecting groups are the 
substituted urethans. Bergmamand Zervas introduced the
39
71benzyloxycarbonyl protecting group (Z) in 1932 and it is 
still one of the most often used urethan protecting groups.
Benzyloxycarbonyl amino acids are obtained almost 
exclusively from benzyloxycarbonyl chloride and the corres­
ponding amino acid in aqueous alkaline solution (Figure 11).
Benzyloxycarbonyl amino acids are stable to mild acid 
and alkaline hydrolysis conditions. Many other acid labile 
protecting groups can be removed easily in the presence of 
a benzyloxycarbonyl group. The Z group is generally cleaved 
by catalytic hydrogenation, although it can be removed 
cleanly by acidolysis as well.
The success of the benzyloxycarbonyl group led to 
extensive investigations in search of other useful urethan 
protecting groups. Several alkyl and aryl urethans, other
than the Z group, have been used for amino protection, how-
72ever, only one, the tert-butoxycarbonyl group (BOC) has
found frequent use.
The BOC group has been used extensively in peptide
synthesis and has been the major method of N-terminal pro-
73tection in solid phase peptide synthesis. The most con­
venient method for the attachment of the tert-butoxycarbonyl 
group has been to react an amino acid or peptide with tert- 
butoxycarbonyl azide (Figure 12). The tert-butoxycarbonyl 
group is stable to alkaline conditions as well as catalytic 
hydrogenolysis but is easily removed under mildy acidic 
conditions. It can be removed selectively in the presence 
of many other protecting groups including benzyloxycarbonyl
Figure 11. The Preparation of Benzyloxycarbonyl Amino Acids.
*The abbreviation now generally accepted for the benzyloxycarbonyl group is Z, 






+ h 2 n-chr-co2h
T 3 it
CH 3 -C-0-C-NH-CHR-C02H (B0C-NH-CHR-C02 H)
ch 3
Figure 12. The Preparation of tert-Butoxycarbonyl Amino 
Acids.
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groups and benzyl esters. However, tert-butyl esters are 
generally not stable to the conditions required for the 
removal of tert-butoxycarbonyl groups.
The use of benzyloxycarbonyl and tert-butoxycarbonyl 
groups for amino protection parallels the use of benzyl and 
tert-butyl esters for carboxylic acid protection. The selec­
tion of amino protecting groups for the synthesis of nor­
surfactin was, therefore, dependent upon the scheme of 
carboxylic acid protection. Having chosen a tert-butyl ester 
for the protection of the carboxylic acid at the C-terminal 
end of depsipeptide 14a, the use of a tert-butoxycarbonyl 
group for amino protection during elongation of the peptide 
was eliminated, since selective removal of one group in the 
presence of the other is not usually possible. However, the 
tert-butoxycarbonyl group could be used in the singular case 
of the N-terminal glutamic acid residue (i.e., PN = BOC in 
14a) since the PN group and the tert-butyl ester must both 
be removed prior to cyclization.
The benzyloxycarbonyl group could be used in the 
early steps of elongation of the peptide chain. The amino 
groups of the first two leucine residues could be protected 
with Z groups which could be removed selectively by catalytic 
hydrogenolysis without disturbing the tert-butyl ester on 
the B-hydroxy acid residue (Figure 13).
The choice of amino protecting groups for the next 
four amino acids becomes more complex. Once the 8 -benzyl 
aspartate residue is incorporated into the peptide chain
4J
* H /Pd
D-CH 0 (CH0) , _CHCHoC0_Bu Z-Leu-|3 v 2' 10 2 2
0
D-CH 3 (CH2 ) 1 qCHCH2 C0 2 Bu H-Leu-] + Z-D-Leu-OH ----
0
H /Pd
D-CH 0 (CH0) n nCHCHoC0oBu Z-D-Leu-Leu-| — ---- >3 2 10T 2 2
O ]
D-CH3 (CH2 )1 0 CHCH2 CO2 Bu H-D-Leu-Leu-
I------------ o ----------------
Figure 13. The Use of the Benzyloxycarbonyl Group (Z)
for Amino Protection of the First Two Leucine 
Residues.
(15), neither a tert-butoxycarbonyl nor a benzyloxycarbonyl 
group can be used for N-terminal protection. Conditions for 
removal of either of these two groups would also remove one 
of the carboxylic acid protecting groups. A protecting group 
must be chosen that can be removed without disturbing the 
benzyl and tert-butyl esters. There are relatively few amino 
protecting groups that meet these criteria.
D-CH 3 (CH2) 1 ()CHCH2 C02 But
15
The 2-p-biphenyl-2-propyloxycarbonyl group (Bpoc-)
75introduced by Sieber and Iselin is a urethan type protect­
ing group that does qualify. Bpoc amino acids are prepared 
in the same manner as tert-butoxycarbonyl derivatives, by 
reaction with the appropriate azide (Figure 14). The rate 
of acidolysis of the Bpoc group is 3000 times greater than 
that for a tert-butoxycarbonyl group and a Bpoc group can,
therefore, be removed selectively without effecting either
7 6
tert-butoxycarbonyl groups or tert-butyl esters. However, 
the instability and difficulties encountered in the prepara­
tion of the 2 -p-biphenyl-2 -propyloxycarbonyl azide along 
with the instability of the Bpoc amino acids are disadvant­








Figure 14. The Preparation of 2-p-Biphenyl-2-propyloxy- 
carbonyl Amino Acids.
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Another amino protecting group that meets the limit­
ations imposed by the presence of both benzyl and tert-butyl
esters is the o-nitrophenylsulfenyl group (NPS-) introduced 
77by Zervas. NPS a m m o  acids are formed by reaction of the 
amino acid with o-nitrophenylsulfenyl chloride in aqueous 
alkaline solution (Figure 15). By treatment with low concen­
trations of HC1 in non-polar solvents, a o-nitrophenylsulfenyl
group can be removed selectively, without disturbing tert-
7 8butoxycarbonyl groups and tert-butyl esters. NPS groups
79can also be removed by treatment with various thiols.
Unlike the 2-p-biphenyl-2-propyloxycarbonylgroup, there are 
no serious problems with stability of either o-nitrosulfenyl 
chloride or the resulting protected amino acids. Because of 
its greater stability, the variety of suitable removal tech­
niques and the fact that the o-nitrophenylsulfenyl group has
been used as a protecting group for the preparation of similar 
41intermediates , it appeared to be a more promising choice 
for the protection of the amino group of aspartic acid and 
the remaining residues in the norsurfactin synthesis (Figure 
16) .
Once suitable protecting groups have been chosen, a 
complete synthetic strategy may be developed. A synthetic 
scheme involving the stepwise elongation of the depsipeptide 
followed by a cyclization via formation of an amide bond is 










D-CH3 (CH2) 1 ()CHCH2 C02 Bu NPS-Asp-D-Leu-Leu]
OBzl
D-CH3 (CH2) 1 ()CHCH2 C0 2 But H-Asp-D-Leu-Leu-| NPS-Val-OH ^
0
OBzl
D-CH3 (CH2) 1 ()CHCH2 C0 2 But NPS-Val-Asp-D-Leu-Leu-. --->  etc.
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Chart I. A Synthetic Strategy for the Stepwise Synthesis of Norsurfactin, 
Variation A.
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Step 1 involves the formation of the ester bond 
between benzyloxycarbonyl-L-leucine and tert-butyl-D-3-hydroxy- 
tetradecanoate to give a protected didepsipeptide. In step 
2  ^the benzyloxycarbonyl group is removed from the didepsi­
peptide by catalytic hydrogenation. The free N-terminal di­
depsipeptide thus obtained is coupled to benzyloxycarbonyl- 
D-leucine (step 3) to afford a protected tridepsipeptide. The 
benzyloxycarbonyl group is again removed by catalytic hydrog­
enation (step 4j and the free N-terminal tridepsipeptide is 
coupled to o-nitrophenylsulfenyl-3-benzyl aspartate (step 5j. 
The selective removal of the o-nitrophenylsulfenyl group by 
treatment with low concentrations of HC1 in a non-polar solvent 
is to be accomplished in step 6^ Consecutive addition of 
o-nitrophenylsulfenyl protected amino acid residues and 
selective cleavage of the o-nitrophenylsulfenyl groups (steps 
7.-13.) would lead to a completely protected acyclic octadepsi- 
peptide derivative. Acidolysis of this derivative under more 
vigorous conditions (step .14) would remove both the o-nitro­
phenylsulfenyl group from the N-terminal glutamic acid residue 
and the tert-butyl ester from the C-terminal D-3-hydroxytetra- 
decanoic acid residue. The free N- and C-terminal octadepsi- 
peptide can then be cyclized (step lj[) and the remaining benzyl 
ester protecting groups removed by catalytic hydrogenation 
(step Ii5) to give norsurfactin.
The scheme just described formed the basis for initial 
synthetic studies. The first consideration was the preparation 
of suitably protected amino and 3 -hydroxy acid residues.
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Racemic g-hydroxytetradecanoic acid (12^ ) was prepared
in 65% yield using Rathke's modification of the Reformatsky
reaction (Figure 17).®^'®^
Dodecanal (16^ ) was allowed to react with ethylbromo-
acetate (1J7) in the presence of zinc dust in a mixed tetra-
hydrofuran-trimethylborate solvent system (1 / 1 , v/v) at room
temperature. The resulting racemic ethyl-g-hydroxytetrade-
canoate (18^ ) was saponified with a solution of potassium
hydroxide in ethanol to afford the desired (+)-g-hydroxytetra-
decanoic acid (12^ ) in 65% overall yield.
Racemic g-hydroxytetradecanoic acid had been previously
resolved on a small scale by Ikawa using D-amphetamine as the
8 2resolving agent. A more feasible large scale resolution 
was developed using (+)- and (-)-a-methylbenzylamine as re­
solving agents. (-)-D-g-Hydroxytetradecanoic acid of greater 
than 96% optical purity was obtained in 14% yield after several 
recrystallizations of the (-)-a-methylbenzylamine salt. (+)- 
L-g-Hydroxytetradecanoic acid was obtained in a similar 
fashion using (+)-a-methylbenzylamine.
A tert-butyl ester was chosen as the protecting group 
for the carboxylic acid moiety of the g-hydroxy acid residue. 
Preparation of tert-butyl esters of similar g-hydroxy acids 
have been reported. For example, as part of early attempts to 
synthesize esperin, tert-butyl-g-hydroxytridecanoate (both 
enantiomers) was prepared by the reaction of tert-butylbromide 
with the silver salt of g-hydroxytridecanoic acid (Figure 18).






)10CHO + BrCH2 C02Et Thf-Tmb >  (±)-CH3 (CH2) 1 ()CHCH2
OH
17 18




Figure 17. The Preparation of Racemic ft-Hydroxytetradecanoic Acid.
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AgNO-
CH3 (CH2)9^HCH2C02H NaOH- ^
OH
CH 3 (CH2 )9 <|HCH2 C02Ag + (CH3)3CBr c o l S L  chrom. >
OH
(95%)
CH3 (CH2 ) 9 (j:HCH2C 02 But  + CH3 (CH2 ) 9CHCH2 C 02 But  
OBufc OH
(7%) (28%)
Figure 18. The Preparation of tert-Butyl-$-hydroxy- 
tridecanoate.^
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gradient elution with a benzene-hexane solvent system was 
required to separate the desired tert-butyl-3 -hydroxytride- 
canoate from 3 -tert-butoxytridecanoic acid tert-butyl ester 
which was also formed in the reaction. This problem and the 
low overall yield of the reaction made this an unattractive 
route to tert-butyl-D-3-hydroxytetradecanoate.
In the synthesis of isariin, tert-butyl-3-hydroxydo-
15decanoate was prepared via a different route (Figure 19).
The acetoxy derivative was first prepared by reaction 
of D-3-hydroxydodecanoic acid with acetic anhydride in pyridine. 
Acid catalyzed esterification with isobutylene gave tert- 
butyl-D-3-acetoxydodecanoate. Saponification of this inter­
mediate afforded the desired tert-butyl-D-3-hydroxydodecanoate 
in 60% overall yield. Despite the increased overall yield in 
this sequence compared to that illustrated in Figure 18, it is 
still relatively unattractive because of the number of steps 
involved. The methods described in Figures 18 and 19 were 
explored, but were abandoned in favor of a new approach.
A major problem in the preparation of tert-butyl 
esters of 3 -hydroxy acids is the prevention of tert-butyl 
ether formation at the hydroxyl group during the esterification. 
It was found that this side reaction could be avoided by using 
dimethylformamide dineopentyl acetal to mediate the esterifi- 
cation of the 3-hydroxy acid with tert-butanol (Figure 20).
Racemic tert-butyl-3-hydroxytetradecanoate (2_0) was 
prepared from D,L-3-hydroxytetradecanoic acid {12) and di­
methylformamide dineopentyl acetal (19j in tert-butanol.
D-CH3 (CH2 )gCHCH2 C02H 
OH
a c 2o






D-CH3 (CH2 )8 CHCH2 C02 But gg°gfl >
OAc
(93%)








d,l-ch3 (ch2 )1 0 chch2 co2h + \:hn(ch3 ) 2
OH (CH3 )3 CCH20
1 2  19
t-BuOH 
2 0 min.




Figure 20. The Preparation of Racemic tert-Butyl-6 -hydroxy- 
tetradecanoate.
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The product was isolated from the reaction mixture in 60% 
yield using dry column chromatography. This method for the 
preparation of tert-butyl esters of 3 -hydroxy acids seems to 
be superior to those previously reported (Figures 18 and 19).
Benzyloxycarbonyl-L-leucine and all other benzyloxy­
carbonyl amino acid derivatives used in this study were
84prepared in the manner shown in Figure 11.
The formation of the ester bond between benzyloxy- 
carbonyl-L-leucine and tert-butyl-D-B-hydroxytetradecanoate 
(step 1 in Chart I) is a key step in the norsurfactin synthetic 
strategy (Figure 21). There are several reports in the liter­
ature on the esterification of amino acids with hydroxy acids 
(depsipeptide bond formation). Of particular significance to
this work was the benzenesulfonic anhydride procedure (using
41benzenesulfonyl chloride) employed by Ovchinnikov to accom­
plish the esterification of a*nitrobenzyl-benzyloxycarbonyl- 
aspartate with tert-butyl-D-B-hydroxytridecanoate (Figure 22).
Another procedure for depsipeptide bond formation 
which has, in many cases, proven to be superior to mixed an­
hydride techniques is the use of N,N'-carbonyldiimidazole 
(CDI). This reagent converts the carboxylic acid group of 
the amino acid to a highly activated imidazolide which then 
reacts with the hydroxy component in the reaction to form an 
ester (Figure 23).
8 5Gisin and Merrifield reported the use of N,N'- 
carbonyldiimidazole for the esterification of tert-butoxy-
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D-CH3 (CH2 )1 ()CHCH2 C0 2 But + Z-Leu-OH 
OH
20 21
D-CH3 (CH2) 1 ()CHCH 2 C0 2 But Z-Leu-| Q ' -j
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D-CH3 (CH2 )9 CHCH2 C0 2 But + Z-Asp-ONBzl THF/Fyr.
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carbonyl-L-valine with benzyl lactate (Figure 24). Although 
Figure 24 illustrates the esterification of an amino acid using 
an oi-hydroxy acid derivative, N,N'-carbonyldiimidazole has been 
used with 6-hydroxy acid derivatives also (Figure 25) . ^
In the present work, formation of the ester bond in 
norsurfactin (step 1, Figure 21) was first attempted using 
racemic tert-butyl-B-hydroxytetradecanoate. Both the N ,N' - 
carbonyldiimidazole and benzenesulfonic anhydride activation 
techniques were studied. The results of several reactions 
are listed in Figure 26.
Under the conditions shown in Figure 26, N,N’- 
carbonyldiimidazole in either methylene chloride or tetra- 
hydrofuran failed to afford any of the desired product 22.
The reactions were monitored by Gas Liquid Phase Chromatog­
raphy; little or no disappearance of the tert-butyl-B-hydroxy- 
tetradecanoate could be detected. When the reactions were 
worked up only starting materials were recovered. Several 
attempts to form esters using benzenesulfonyl chloride also 
failed to produce any of the desired product.
In view of the success of these procedures in pre­
viously published reports, our results seemed to be anomalous. 
The lack of success, might be attributed, at least in part, 
to steric hindrance. The steric bulk of the isobutyl side 
chain on the leucine residue and of the tert-butyl ester on 
the 6-hydroxy acid residue might conspire to inhibit ester­
if ication. It was found that when benzyloxycarbonylglycine 
(23) was substituted for benzyloxycarbonyl-L-leucine (21) in
CH., CH-| 3 | 3
H0-CHC02Bzl + BOC-Val-OH c H ^ C ^ / ^ d a y s  >  B0C-Val-0-CHC02Bzl
(97%)
Figure 24. The Formation of a Depsipeptide Bond Using N,N'-Carbonyldiimidazole,





Figure 25. Depsipeptide Bond Formation Using a 3-Hydroxy Acid Derivative.
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1  ^ CPI (1 eg.)
; CH2Cl2/3 days * no product isolated
„  CPI (1 eg.)
} THF/5 days ^
PhSO^Cl
3)  A-.--- ^pyridine ^
R = CH3 (CH2 )10-
Figure 26. The Attempted Esterifications of Benzyloxycarbonyl- 
L-leucine with P,L-tert-Butyl-3-Hydroxytetrade- 
canoate.
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the esterification reaction using benzenesulfonyl chloride, 
the desired esterified product 2£ was obtained in approxi­
mately 75% yield (Figure 27). This result seems to indicate 
that steric hindrance due to bulk of the side chain on leucine 
was a factor inhibiting the previous esterification attempts.
In order to further investigate steric effects,
esterifications were attempted using D ,L-methyl-3-hydroxy-
tetradecanoate (25). If the tert-butyl ester is also steric-
ally hindering esterification then the corresponding methyl
ester should provide a greater yield of depsipeptide. D,L-
Methyl-3-hydroxytetradecanoate was prepared as shown in
Figure 28. The use of dimethylformamide dineopentyl acetal
in methanol gave the desired methyl ester (2_5) in 65% yield
based on GLC analysis of the reaction mixture. Esterifica-
8 6  87tion with diazomethane ' proved to be a superior method 
affording a 98% isolated yield of D ,L-methyl-3-hydroxytetra- 
decanoate. The results from esterifications using D,L- 
methyl-3-hydroxytetradecanoate are shown in Figure 29.
When benzyloxycarbonyl-L-leucine (2JJ was esterified 
with D,L-methyl-3-hydroxytetradecanoate (25) using both 
benzenesulfonyl chloride and N,N'-carbonyldiimidazole, crude 
didepsipeptide (26) was isolated in low yield (25% and 40%, 
respectively). The esterification of benzyloxycarbonylglycine 
(23) with the 8-hydroxy methyl ester (25) under the same 
conditions gave substantially higher yields (70% and 62%, 
respectively). These results would seem to indicate that 
the steric bulk of the tert-butyl ester in compound 2 0 may
PhS02Cl
D,L-RCHCH2C02Bu + Z-Gly-OH pyridine > D,L-RCHCH2C02Bu Z-Gly-j
Ah-------------------------------------- I--------o -------- 1
—  —  —  (.75%)
R = CH3 (CH2 )10-
Figure 27. The Esterification of Benzyloxycarbonylglycine with D,L-tert-Butyl- 
B-hydroxytetradecanoate.
d ,l-ch3(ch2)10chch2co2h — > d ,l-ch3(ch2)10chch2co2ch3
OH OH
12 25
^ C H N ( C H 3)2/CH3OH ----- ^  (65%)
(ch3)3cch2o
B. CH2N2 ----- ^  (98%)
Figure 28. The Preparation of D,L-Methyl-B-hydroxytetradecanoate,
PhS02Cl
D , L-RCHCHoC0oCHo + Z-Leu-OH ------ >  D,L-RCHCHoC0oCH, Z-Leu-,| 2 2 3 pyridine ^  i 2 2 3 1
OH ■---------- 0 --------- '




c h 2c i 2
PhS02Cl
D,L-RCHCH2C02CH3 + Z-Gly-OH pyridine ^  D,L-RCHCH2C02CH3 Z-Gly-i
OH I---------- 0 --------- »
25 23 (70%) 27
+ « ! CDI > I
CH2C12 (62%) 
R = CH3 (CH2)10-
Figure 29. Esterif ications Using D, L-Methyl-(5-hydroxy tetradecanoate.
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also be a factor contributing to the failure of the attempted 
esterifications shown in Figure 26. In the esterification of 
benzyloxycarbonyl-L-leucine, a detectable yield of didepsi- 
peptide was obtained with D,L-methyl-B-hydroxytetradecanoate 
(Figure 29) while no esterified product could be isolated 
when D,L-tert-butyl-B~hydroxytetradecanoate was used (Figure 
26). However, no such increase in yield was observed for the 
corresponding esterifications of benzyloxycarbonylglycine. 
This result might be expected since glycine has no bulky 
side chain to interact with the tert-butyl ester. It should 
be noted that this is also the case with the aspartic acid 
derivative shown in Figure 22. There are no groups a to the 
8-carboxylic acid moiety of the aspartic acid derivative 
that is being esterified. A 69% yield of the desired product 
was obtained even though the sterically pretentious tert- 
butyl- 8-hydroxytridecanoate was used.
Another source of inhibition to the esterification 
might be the long hydrocarbon chain of 8-hydroxytetradecanoic 
acid. In order to obtain information on the possible influ­
ences that this group might impose on the reaction, a series 
of esterifications were attempted using D ,L-methyl-g-hydroxy- 
butyrate (28). If the hydrocarbon chain of the 8-hydroxy­
tetradecanoic acid esters is contributing to steric hindrance 
in the reaction, then an increase in yield would be expected 
since this source of hindrance is not present in the 8- 
hydroxybutyrate.
bb
D,L-Methyl-3-hydroxybutyrate was prepared from D,L- 
3-hydroxybutyric acid and diazomethane. The results of 
several Z-amino acid esterifications using D,L-methyl-3- 
hydroxybutyrate are summarized in Figure 30.
The results in Figure 30 show that there was no 
increase in esterification yield when D ,L-methyl-3-hydroxy- 
butyrate, rather than D,L-methyl-3“hydroxytetradecanoate 
(Figure 29), was the alcohol component. This would seem to 
indicate that the hydrocarbon chain of the 3“hydroxytetra- 
decanoic acid esters is not a major influence. However, 
there was a significant decrease in yields observed when 
proceeding from amino acids with small or no a-side chain 
(benzyloxycarbonyl-L-alanine, 30^ , and benzyloxycarbonylgly- 
cine, 2J3) to an amino acid derivative with a large bulky 
a-side chain (benzyloxycarbonyl-L-leucine, 21_) . Along with 
the observations summarized in Figure 29, this supports the 
argument that the side chain steric bulk is an important 
factor.
In summary, it would seem that inhibitory influences 
in these types of esterifications result primarily from the 
bulk of the a-side chain of the amino acid derivative. The 
size of the ester group on the 3-hydroxy acid also seems to 
exert some influence but the size of the 3~side chain on the 
3-hydroxy acid is not a major factor.
The results of the esterification study indicate that 
the formation of the ester bond between benzyloxycarbonyl-L-
PhSO_Cl
CHCHoC0_CHo +I 2 2 j Z-Gly-OH
A
pyridine -> D,L-CHoCHCHoC0-CH_ 3 I 2 2 3 Z-Gly-,
1OH 1---------o -----
28 23 (60%)* 29
PhSO_Cl
+ Z-Ala-OH Apyridine -> d ,l -c h 3c h c h 2c o 2c h 3 Z-Ala,
20 1--- -----0 ... 1
(57%)* 31
PhS0oCl
" + Z-Leu-OH Apyridine d ,l -c h 3c h c h 2c o 2c h 3 Z-Leu-j 
121 1-------- 0
(34%)* 32
*Yields are based on GLC of crude product.
Figure 30. Esterification of Several Z-Amino Acids with D,L-Methyl-fc-hydroxybutyrate.
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leucine and D-tert-butyl-g-hydroxytetradecanoate in step 1 
(Chart I) cannot be accomplished in acceptable yield by 
previously published methods.
Despite the lack of success in this initial attempt, 
the basic strategy of prior formation of the ester bond 
leading to a final cyclization through an amide bond as shown 
in Figure 8 still appeared to be the most desirable approach. 
In order to maximize the chance of success in the initial 
formation of the ester bond, a new synthetic strategy was 
developed (Chart II).
In Chart II the protecting group for the carboxylic 
acid moiety of g-hydroxytetradecanoic acid is a p-nitrobenzyl 
ester (ONBzl). The utility of this group for the C-terminal
protection of amino acids during peptide synthesis was first
8 8 8 9shown by Schwarz and Schwyzer. It has been found that
p-nitrobenzyl esters display a much greater stability under 
the acidic conditions used to remove benzyloxycarbonyl 
groups than do benzyl esters. This allows selective acid- 
olysis of benzyloxycarbonyl groups to be accomplished in 
the presence of p-nitrobenzyl esters. Also, p-nitrobenzyl 
esters have a greater tendency to crystallize than do benzyl 
esters, and this became an important consideration in the 
synthetic strategy for norsurfactin. All of the previously 
prepared derivatives of g-hydroxytetradecanoic acid were 
either oily compounds or low melting solids that were diffi­
cult to purify. It was hoped that the introduction of a 


































































Chart II. A Synthetic Strategy for the Stepwise Synthesis of 
Norsurfactin, Variation B.
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impart a higher degree of crystallinity to the intermediates, 
hopefully making them easier to isolate and purify.
If the hydrogenolytically labile £-nitrobenzyl ester 
is to be used for protection of the carboxylic acid moiety 
of the 3-hydroxy acid residue (as in Chart II) a general 
reversal in strategy for carboxylic acid protection (compared 
to the scheme outlined in Chart I) is required. The side 
chain carboxylic acid groups of aspartic and glutamic acids 
must be protected by tert-butyl esters if the previously 
stated criteria for carboxylic acid protection are to be 
complied with. A similar reversal is required for the N- 
terminal protecting groups on the first two leucine residues.
A tert-butoxycarbonyl group (BOC-) must now be used for the 
N-terminal protection of these residues. The BOC group can 
be removed under mildly acidic conditions without disturbing 
the C-terminal p-nitrobenzyl ester. The use of an extremely 
acid sensitive N-terminal protecting group, such as the o- 
nitrophenylsulfenyl group, is again required when the 3- 
tert-butylaspartate derivative is introduced, and for all 
subsequent couplings, so that the tert-butyl ester can be 
retained. Stepwise build up of the peptide would proceed in 
the same manner as shown in Chart I. Deprotection of the 
linear octadepsipeptide at both C- and N-terminal positions 
and a cyclization followed by removal of the tert-butyl esters 
on the side chains of the aspartic and glutamic acid residues 
should lead to norsurfactin.
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A closer examination of the strategy outlined in 
Chart II reveals a possible problem. The literature states 
that o-nitrophenylsulfenyl protecting groups can be selec­
tively removed in the presence of tert-butyl esters by
7 8exposure to very mildly acidic conditions. However, the 
repeated exposure of the tert-butyl ester on the aspartic 
acid residue to such conditions required by the strategy 
outlined in Chart II, is cause for concern. After the in­
corporation of the 3-tert-butyl aspartate residue into the 
depsipeptide, successive removal of o-nitrophenylsulfenyl 
groups during further stepwise elongation of the peptide 
chain would expose this tert-butyl ester to acidic conditions 
five times. This could lead to partial cleavage of the tert- 
butyl ester and possibly to the formation of small amounts
of 3-aspartyl peptides during subsequent peptide coupling 
steps.
In order to avoid this potential problem, an alter­
native fragment type synthetic strategy was developed (Chart 
III). The tetradepsipeptide fragment B would be prepared 
using the strategy summarized in Chart II. The tetrapeptide 
fragment A would be prepared in a stepwise fashion also.
The C-terminal carboxylic acid group on valine can be pro­
tected as a methyl ester since there are no alkaline sensitive 
groups in the tetrapeptide. Stepwise elongation would be 
accomplished using a Z group for the N-terminal protection of 
new units during coupling; hydrogenolysis would be suitable
D-Leu Val Asp D-Leu D-HOCHRCH~CO~HLeuLeu..u



















R = CH3 (CH2)10-
Chart III. Fragment Synthetic Strategy for Norsurfactin, Variation A.
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for removal of the Z group prior to the next coupling step.
The side chain y-carboxylic acid moiety of the N-terminal
glutamic acid residue would be protected by a tert-butyl
ester. The C-terminal ester on the completely protected
tetrapeptide would be selectively removed by saponification.
The selective saponification of methyl esters in the presence
90 91of tert-butyl esters has been reported many times. ' A 
(4+4) fragment coupling (tetrapeptide A plus tetradepsipeptide 
B) would lead to the completely protected octadepsipeptide C. 
Simultaneous removal of the N-terminal benzyloxycarbonyl 
group on the glutamic acid residue and the £-nitrobenzyl 
ester on the C-terminal g-hydroxy acid residue would give 
the partially protected octadepsipeptide D. Cyclization 
followed by acidic removal of the remaining tert-butyl ester 
protecting groups would lead to norsurfactin.
If this scheme were followed, then the tert-butyl 
ester on the g-carboxylic acid residue of aspartic acid 
would only be exposed to acidic conditions once, during 
removal of the o-nitrophenylsulfenyl protecting group on 
the tetradepsipeptide prior to the fragment coupling.
Following the strategy outlined in Chart III, the 
preparation of p-nitrobenzyl-g-hydroxytetradecanoate was 
accomplished using a procedure similar to that for attachment 
of amino acid residues to chloromethylated polystyrene solid 
supports in the solid phase peptide synthesis technique 
(Figure 31).92
Et^N




Figure 31. The Preparation of D and L p-Nitrobenzyl-8-hydroxytetradecanoate
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In separate experiments, both D and L-3-hydroxytetra- 
decanoic acid (12) were treated with p-nitrobenzyl chloride
(33) in the presence of triethylamine in ethyl acetate solvent. 
The desired D and L p-nitrobenzyl-B-hydroxytetradecanoates
(34) were obtained as crystalline solids (m.p. 55°) in 77% 
yield. It was also possible to recover the unreacted optically 
active B-hydroxytetradecanoic acids from the reaction mixtures.
The tert-butoxycarbonyl amino acids to be used in the
synthesis were prepared by the procedure of Weinstein using
93tert-butoxycarbonyl azide as shown in Figure 12.
The problem of the formation of the ester bond between 
tert-butoxycarbonyl-L-leucine and D-p-nitrobenzyl-B-hydroxy- 
tetradecanoate remained to be solved. It was decided to 
attempt the initial reactions using tert-butoxycarbonyl-D- 
leucine and L-p-nitrobenzyl-3-hydroxytetradecanoate as model 
compounds. In this way the D-£-nitrobenzyl-B-hydroxytetra- 
decanoate needed for the synthesis of norsurfactin could be 
conserved until satisfactory conditions for the esterification 
were developed. The enantio-intermediates obtained using the 
model compounds should have physical properties identical to 
those of the norsurfactin intermediates. Similarly the rates 
of reactions to form enantio-intermediates should be the same. 
Carrying these enantio-intermediates through the remaining 
steps outlined in Chart III would result in the preparation 
of a norsurfactin diastereomer (the configurations of the 3- 
hydroxy acid residue and the C-terminal leucine residue being 
opposite to those found in norsurfactin). The physical and
76
biological properties of such a compound would be of added 
interest.
It was determined that the esterification of tert- 
butoxycarbonyl-D-leucine (35^ ) with L-g-nitrobenzyl-8-hydroxy- 
tetradecanoate (L-34) could be satisfactorily accomplished 
under the conditions shown in Figure 32. The desired ester­
ified product was obtained as an oily material in 90% yield 
when three equivalents of both tert-butoxycarbonyl-D-leucine
(35) and N,N'-carbonyldiimidazole were used and the reaction 
was allowed to proceed for seven days. The attainment of 
high yields by using a large excess of carboxylic acid sub­
strate and N,N'-carbonyldiimidazole for the formation of 
depsipeptide bonds had not been reported in the literature at 
the time this reaction was carried out, but has since been 
substantiated.^
Esterification of tert-butoxycarbonyl-L-leucine (37) 
with D-£-nitrobenzyl-B-hydroxytetradecanoate (D-34) was 
carried out under similar conditions (Figure 33). In Hfiis 
case the reaction was allowed to proceed for only five days 
and only a 76% yield of esterified product was obtained.
Shortly after these results were obtained, a synthesis
of isariin was reported in which similar esterifications were
15attempted (Figure 34).
The low yields obtained using procedures A through C 
and particularly with the benzenesulfonyl chloride procedure 
B, substantiate our earlier failures in the attempts to 
esterify leucine derivatives (Figures 26 and 29). A 59%
L-CH3 (CH2)10CHCHCH2CO2NBz1 + BOC-D-Leu-OH (3 eq.) § § ^ 1 3/Todays 
OH 35
L-34




Figure 32. The Esterification of tert-Butoxycarbonyl-D-leucine with L 
Nitrobenzyl-3-hydroxytetradecanoate.
(-)-D-CH3 (CH2)10CHCH2CO2NBz 1 + BOC-L-Leu-OH (3 eq.) C H ^ C l ^ / w I y s  >
OH
D-34 37




Figure 33. The Esterification of tert-Butoxycarbonyl-L-leucine.
CH3 (CH2 )g(j:HCH2C02But + Z-Val-OH --- > CH3 (CH2 ) gCHCI^CC^Bi^ Z-Val^
OH I-------- 0 -----------
A: DCC --->  (11%)
B: PhS02Cl  ^  (6%)
C: (CH3)2CHCH2OCOCl --- >  (18%)
D: CDI ^ Im- > (59%)
Figure 34. The Results of Esterification Reactions Attempted in Isariin
15Synthetic Studies.
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yield of esterified product was reported using one equivalent 
of N,N'-carbonyldiimidazole for activation in a reaction 
catalyzed by a small amount of a sodium-imidazole solution 
in tetrahydrofuran (procedure D). Our failure to obtain any 
esterified product in a similar system (Figure 26) using N,N'- 
carbonyldiimidazole alone would seem to make the catalytic 
procedure significant. Presumably the catalysis is a result 
of imidazole anion formation as shown in Figure 35.
It appears probable that the imidazole anion formed 
from the reaction with sodium removes a proton from the 
hydroxyl group of the 6-hydroxy ester to form an oxygen 
anion. The rate of attack of this anion on the activated 
amino acid imidazolide is presumably faster than that of 
the unionized hydroxy group thus resulting in an increased 
yield of the esterified product.
When sodium-imidazole catalysis was used along with 
the conditions shown in Figure 32, a 97% yield of esterified 
product was obtained after allowing the reaction to proceed 
for only three days (Figure 36).
Continuing the synthetic scheme in Chart III, the
tert-butoxycarbonyl group was cleanly removed from the L,D-
didepsipeptide 3£ using boron trifluoride diethyletherate in
94
acetic acid (Figure 37). The free N-terminal L,D-didepsi- 
peptide 39_ was obtained in 93% yield. The D ,L-didepsipeptide 
38 was similarly deprotected to give the free N-terminal 
D,L-didepsipeptide 40 in 92% yield.
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2 N ~ L  + 2 Na° ---- >  2
V '  V '
N N ( i a (+) + R-CHCHoC0~But| 2 2
Of)H
^  tN NH + R-CHCHoC0_Bu
^  I 2 2
0 (-)N a (+)
I
Z-NH-CHR'-i
t  i' ^ ^ (-R-CHCHoC0~Bu Z-NH-CHR'-C-i + N v
I U  o ____________ ] ^
> Na+ + H2
II r = \
C-N
 »
Figure 35. A Presumed Mechanism for the Sodium-imidazole 
Catalyzed Esterification.












L-CH., (CH0) . f.CHCH0CO»NBzl BOC-D-Leu-i    >  L-CH-, (CH0) . nCHCHoC0oNBzl H-D-Leu-J 2 1U| 2 2 I HOAc 3 2 101 2 2
 0 --------
 " ^  ; !
3(5 39
(93%)
Figure 37. The Removal of a tert-Butoxycarbonyl Group Using Boron Trifluoride 
Diethyletherate.
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Having formed the required ester bonds and removed 
the N-terminal protecting groups from the resulting didepsi- 
peptides, the elongation of the depsipeptide fragment is the 
next step in the scheme shown in Chart III. This involves 
the formation of a peptide bond between tert-butoxycarbonyl- 
D-leucine and didepsipeptide £0 to form the protected tri- 
depsipeptide 4_1 (Figure 38).
Numerous procedures have been developed for the 
formation of peptide bonds in very high yields.* The proce­
dure that has had the greatest impact on peptide synthesis 
is the use of N,N'-dicyclohexylcarbodiimide (DCC) as a con­
densing agent. Sheehan and Hess first introduced the use of
97this reagent for the formation of peptide bonds in 1955.
Numerous other coupling reagents have since been shown to
give equally good results, but N,N*-dicyclohexylcarbodiimide
is still one of the most often used methods and is the primary
coupling method used in Merrifield's solid phase peptide
73synthesis technique. However, in spite of its obvious
utility, N,N'-dicyclohexylcarbodiimide can also cause problems
51when used as a solution coupling reagent. For example, the
formation of hard to remove by-products and the occurrence
of significant amounts of racemization on the free C-terminal
activated residue during the formation of some peptides has
98been observed in many cases. In order to avoid these
*For reviews of coupling procedures for peptide synthesis 









-CH3 (CH2) 1()CHCH2C02NBzl BOC-D-Leu-Leu-,
O
41
The Elongation of the Depsipeptide Fragment.
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problems, other methods of peptide bond formation were in­
vestigated in this study.
One coupling procedure that has proven to be very 
successful is the N,N'-dicyclohexylcarbodiimide mediated 
formation of activated esters. This general procedure is 
outlined in Figure 39. Condensation of an appropriate 
activating hydroxylic reagent with an N-terminally protected 
amino acid using DCC yields an activated amino acid ester. 
Reaction of the active ester with a C-terminally protected 
amino acid gives a fully protected dipeptide.
The use of N-hydroxysuccinimide with DCC to form
active succinimido-amino acid esters is an example of this
method (Figure 40). This procedure generally gives high
99yields and very little racemization. However, the forma­
tion of by-products resulting from a reaction between N ,N' - 
dicyclohexylcarbodiimide and N-hydroxysuccinimide has been 
reported.
Another active ester procedure which promotes the 
rapid formation of peptide bonds was introduced by Konig 
and Gieger.^^'*' Active esters formed from the reaction of 
N-terminally protected amino acid derivatives with 1-hydroxy- 
benzotriazole (HOBT) and DCC (Figure 41) gave acceptable 
yields of peptides with very little racemization.
An independent racemization study of this method 
using the isotopic dilution technique^23 indicated that the 
extent of racemization of the activated amino acid is less 
than 0.09% when the coupling is carried out in tetrahydro-
X-NH-CHR-CO-H + R— - OH >  X-NH-CHR-CO„R . ^ act. 2 act
X-NH-CHR-CO„R . + NH^-CHR1-CO-Y ------- >2 act. 2 2
X-NH-CHR-CO-NH-CHR'-C02Y




DCCX-NH-CHR-C0oH + R—   OH - >  X-NH-CHR-CO.R .
2 act. 2 act
X-NH-CHR-CO_R . + NH--CHR'-CO„Y ------- >2 act. 2 2
X-NH-CHR-CO-NH-CHR'-C02Y




X-NH-CHR-C02H + N-OH DCC X-NH-CHR-CO„-N





Figure 41. The Formation of 1-Hydroxybenzotriazole 
Active Esters.
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102furan. An added advantage of this procedure is that the
active ester intermediate need not be isolated prior to reac­
tion with the C-terminally protected residue. Since it is also 
a clean and rapid procedure, the DCC-HOBT method appeared to 
be very attractive for use in the norsurfactin synthetic 
sequence.
It was decided to carry the enantiomeric model compound 
concept one step further in order to investigate the formation 
of peptide bonds with depsipeptide intermediates. The prepara­
tion of the L,D,L-tridepsipeptide £2 was accomplished in 98% 
yield using the DCC-HOBT procedure (Figure 42). Similarly, 
the protected D,L,D-tridepsipeptide ££ was obtained in 98% 
yield using the same procedure.
D-CH.,(CH„).nCHCH_CO_NBzl BOC-D-Leu-Leu o z 1U | 2 2
I---------------- o ----------------
11
The tert-butoxycarbonyl protecting groups on compounds 
42 and £3 were removed using boron trifluoride diethyletherate 
in acetic acid to give the free N-terminal tridepsipeptides 
44 and ££ in 93% and 94% yields, respectively. Tridepsipeptide 
44 was then used as a model compound in exploratory studies 




L-CH3 (CH2 ) 1()CHCH2C02NBzl BOC-Leu-D-Leu]
42
(98%)
Figure 42. The Formation of the L,D,L-Tridepsipeptide.
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L-CH3 (CH2 )1qCHCHoC0oNBz 1 H-Leu-D-Leu-
44
D-CH3 (CH2 ) 10CHCH2CO2NBzl H-D-Leu-Leu-i
  0  1
45
OBu*1
D-CH3 (CH2)10CHCH2CO2NBzl H-Glu-D-Leu-Leu-I-du-D-Leu-J ieuj
Fragment B
The preparation of the suitably protected aspartic
acid residue needed for the elongation of the depsipeptide
fragment was accomplished by the series of reactions shown
in Figure 43. Benzyloxycarbonyl-(B-tert-butyl)-aspartate
103(46) was prepared by the method of Schwyzer. The benzyl­
oxycarbonyl group was then removed by catalytic hydrogenation 
to give 6-tert-butylaspartate (41) in 84% yield. Reaction 
of this derivative with o-nitrophenylsulfenyl chloride (48) 
in aqueous sodium hydroxide solution followed by treatment 
with dicyclohexylamine (DCHA) gave the o-nitrophenylsulfenyl- 
(6-tert-butyl)-aspartate a-dicyclohexylamine salt (49) in 
60% yield. o-Nitrophenylsulfenyl-(6-tert-butyl)-aspartate 
(50) was obtained quantitatively upon treatment of salt 4j^  
with 10% aqueous citric acid.
OBut OBufc
| H2/Pd | 1) NaOH




NPS-Asp-OH* DCHA L0% ?.3:tr:i-.c acld •>, NPS-Asp-OH 
£9 50
(60%) (100%)
Figure 43. The Preparation of o-Nitrophenylsulfenyl-(6- 
tert-butyl)-aspartate (50).
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The model tetradepsipeptide !51 was then prepared from 
compound 50 and tridepsipeptide 44^  in 70% yield using the 1- 
hydroxybenzotriazole procedure (Figure 44).
Having prepared tetradepsipeptide fragment 5JL, a 
diastereomeric model for fragment B in Chart III, attention 
was turned to the preparation of the tetrapeptide fragment A 
needed to complete the synthetic strategy summarized in Chart 
III.
Benzyloxycarbonyl-(8-tert-butyl)-L-glutamyl-L-leucyl- 
D-leucyl-L-valine methyl ester (59j was prepared as outlined 
in Figure 45.
The protected dipeptide 5£ was prepared in 82% yield
104from L-valine methyl ester hydrochlorxde (53^ ) and benzyl- 
oxycarbonyl-D-leucine (52^ ) by the DCC-HOBT procedure using an 
equivalent of N-methyl morpholine (NMM) to free the amino 
group of valine from the hydrochloride salt. The benzyloxy­
carbonyl group was removed hydrogenolytically and the result­
ing free N-terminal dipeptide 55^  was coupled with benzyloxy- 
carbonyl-L-leucine (21) to yield the protected tripeptide 56^  
in 55% yield (from dipeptide 5j4) . The free N-terminal tri­
peptide 5^ 7 was obtained in 86% yield by hydrogenolytic removal 
of the benzyloxycarbonyl group from 56^ . The completely pro­
tected tetrapeptide 59 was prepared from tripeptide 51_ and
105benzyloxycarbonyl-(y-tert-butyl)-glutamate (58^ ) xn 86% 
yield using the DCC-HOBT procedure.
95
OBufc







I— ----------------  O ---------------- -
51.
(70%)
Figure 44. The Preparation of Tetradepsipeptide 51.
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Figure 45. The Preparation of the Protected Tetrapeptide 
Fragment 59.
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With the preparation of both a model tetradepsipeptide 
51 and tetrapeptide 59^  having been accomplished, only the 
selective removal of the N- and C-terminal protecting groups 
remained to be achieved before a fragment coupling could be 
attempted. The o-nitrophenylsulfenylgroup had to be removed 
from tetradepsipeptide 5^1 and the methyl ester had to be re­
moved from tetrapeptide in order to obtain the required 
intermediates.
The selective removal of o-nitrophenylsulfenyl groups
from depsipeptides also containing tert-butyl esters has been
41reported by Ovchinnikov (Figure)46. In both examples a and 
b in Figure 46, the o-nitrophenylsulfenyl group was removed 
from the depsipeptide, cleanly and in high yield, by brief 
treatment with two equivalents of hydrogen chloride as a 0.3N 
solution in chloroform. The solid depsipeptide hydrochlorides 
were obtained in good purity by triturating the residue ob­
tained by concentration of the reaction mixtures with 
petroleum ether.
This procedure was followed using model tetradepsi­
peptide 51^  (Figure 47). Several attempts to selectively 
cleave the o-nitrophenylsulfenyl group led only to complex 
mixtures of oily products. Thin layer chromatographic 
analysis of the mixtures showed ninhydrin positive compounds 
as well as starting protected tetradepsipeptide indicating 
that some cleavage of the o-nitrophenylsulfenyl group had 
occurred. However, recovery of the desired tetradepsipeptide 
hydrochloride (60•HC1) from these oily mixtures could not
D-CH-. (CH ) CHCH CO Bufc D-CH, (CH-) _CHCH_CO_But
3 2 9 I 2 2 0.3N HC1/CHC1 3 2 9 1 2 2
<a) O '
15 m m .  R.T,
NPS-Asp-Val-Leu-D-Leu-ONBzl HC1*Asp-Val-Leu-D-Leu-ONBzl
(96%)
D-CH, (CH ) -CHCH-CO Bu*1 D-CH- (CH- ) -CHCH-CO-B^
I 0.3N HC1/CHC1, y ‘ 2 2
I (2 eg.) J
(b) OBzlI
0 15 min. R.T. 0
OBzl
1 I I I
NPS-Glu-Asp-Val-Leu-D-Leu-ONBzl HC1* Glu-Asp-Val-Leu-D-Leu-ONBzl
(99%)
Figure 46. The Selective Removal of o-Nitrophenylsulfenyl Protecting Groups in the 












(no product isolated) 60*HC1
Figure 47. Attempted Selective Removal of the o-Nitrophenylsulfenyl Group 
Using HC1 in Chloroform.
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be accomplished
Several alternative o-nitrophenylsulfenyl removal
techniques were also attempted using model tetradepsipeptide
51 (Figure 48).
The use of ammonium thiocynate with 2-methyl indole
106(procedure A) under the conditions described by Wtlnsch re­
sulted in very little detectable cleavage of the o-nitrophenyl­
sulfenyl group from the tetrapeptide. Treatment with thiophenol
79in dimethylformamide (procedure B) gave similar results.
Attempted cleavage of the o-nitrophenylsulfenyl group using
88% formic acid (procedure C ) , under the conditions reported 
74by Kmoshita for the selective removal of N-terminal tert- 
butoxycarbonyl groups from peptides containing tert-butyl 
esters, again resulted in a complex oily mixture and none of 
the desired free N-terminal tetradepsipeptide could be ob­
tained.
At this juncture it appeared that an efficient proce­
dure for the selective removal of the o-nitrophenylsulfenyl 
group from tetradepsipeptide 51 could not be achieved. There­
fore, the completion of the fragment type synthetic scheme 
outlined in Chart III was not possible.
In order to continue with the synthesis and also 
utilize the previously prepared synthetic intermediates, a 




L-CH3 (CH2 )1QCHCH2C02NBzl NPS-Asp-Leu-D-Leu
------------- O ------------------ ]
51
OBu'
L-CH3 (CH2) ^ qCHCH2C02NBz 1 H-Asp-Leu-D-Leu- 
------------ O ------------------
60
A: NH4SCN/ V -  ch. 106
B: —  SH/DMF 79
C: HC02H (88%) 74






























































This route is similar to the scheme outlined in 
Chart III, however, instead of a (4+4) fragment coupling 
step, a (5+3) fragment coupling is proposed.
The Chart IV scheme does not require the use of acid 
sensitive N-terminal protecting groups such as the o-nitro­
phenylsulfenyl group. By incorporating both side chain tert- 
butyl ester protecting groups into the five residue peptide 
fragment A ' , the tridepsipeptide fragment B' remains free of 
acid sensitive esters. The N-terminal leucine residue on 
the tridepsipeptide is protected by a tert-butoxycarbonyl 
group which can be removed with mild acid leaving the C- 
terminal p-nitrobenzyl ester intact. Both the tridepsipeptide 
fragment B' (compound 45) and its enantiomer (compound 44) 
had been prepared previously during this project.
Protection of the pentapeptide fragment in Chart IV 
is analogous to protection of the tetrapeptide fragment in 
Chart III. The a-carboxylic group of the aspartic acid 
residue can be protected as a methyl ester. This ester 
should then be removable by selective saponification without 
disturbing either of the tert-butyl ester groups to afford 
the pentapeptide fragment A'.* A (5+3) fragment coupling
*It has been shown that 3-tert-butyl esters on aspartic acid 
residues incorporated in peptides are, in some cases, base 
labile due to participation of the C-terminal amide nitrogen 
in ester hydrolysis.107,108 This unusual sensitivity to 
base should not be encountered in this case since the 
aspartic acid residue is the C-terminal residue of the 
peptide and there is no C-terminal amide nitrogen to assist 
saponification of the tert-butyl ester.
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would lead to the same protected octadepsipeptide derivative 
(C) proposed in Chart III. The remaining steps leading to 
norsurfactin are identical in both the Chart III and Chart 
IV schemes.
The preparation of peptide fragment A' would normally 
proceed in a stepwise fashion from the a-methyl-8-tert-butyl 
aspartate residue (in a manner similar to the preparation of 
the tetrapeptide fragment A in Chart III) followed by selec­
tive saponification of the C-terminal methyl ester. However, 
it was decided to attempt the preparation of the pentapeptide 
A 1 using the previously prepared tetrapeptide 5_9, as shown in 
Figure 49. The methyl ester was removed from tetrapeptide 
59 using 3.1 equivalents of sodium hydroxide in a 7 5% aqueous 
dioxane solution. The free C-terminal tetrapeptide £0 was
obtained in 71% yield. Tetrapeptide £0 was then coupled with
109a-methyl-g-tert-butyl aspartate hydrochloride (£1) using 
the DCC-HOBT technique, with prior neutralization of the 
hydrochloride salt by addition of N-methylmorpholine (NMM). 
The desired protected pentapeptide £2 was obtained in 65% 
yield. The C-terminal methyl ester was selectively saponi­
fied using 3.1 equivalents of sodium hydroxide in 75% aqueous 
dioxane to afford the desired pentapeptide fragment £4 in 
82% yield.
Having successfully prepared the desired deprotected 
peptide and depsipeptide fragments, the (5+3) fragment 
couplings were attempted. The DCC-HOBT technique was again 
chosen to mediate peptide bond formation and the time of
Z-Glu-Leu-D-Leu-Val-OMe NaOH (3.1 eg.) 












Figure 49. The Preparation of Pentapeptide A ' .
(3.1 eg.) ^  
Dioxane
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reaction was extended to five days. Using this method, the 
fragment coupling between pentapeptide 64^  and model tridepsi­
peptide 44^  gave the protected octadepsipeptide 6!5 in 60% 
yield (Figure 50).
When this procedure was repeated using pentapeptide 
64 and tridepsipeptide 45_, compound ([6, the acyclic octa­
depsipeptide precursor to norsurfactin, was obtained in 75% 
yield (Figure 51).
Removal of the benzyloxycarbonyl group from the N- 
terminal glutamic acid residue and the p-nitrobenzyl ester 
from the C-terminal D-g-hydroxytetradecanoic acid residue 
of octadepsipeptide ^6 was accomplished by catalytic hydrog­
enation (Figure 52). The N- and C-terminally deprotected 
octadepsipeptide 67_ was obtained in 94% yield.
The next step in the synthetic scheme (Chart IV) is 
the cyclization of derivative 6J7. The tendency of a linear 
peptide to cyclize is generally dependent upon the number and 
the configuration of the residues in the peptide. The condi­
tions required for the successful cyclization of peptide 
derivatives via the formation of peptide bonds are not the 
same as those required for normal peptide bond formation.'*'
Best results have been obtained when the carboxyl activation 
and cyclization steps are separable. Cyclization, like 
normal peptide bond formation, requires an activated carboxyl 
group and a free amino group. Activation of the carboxyl 
group being a bimolecular process is generally performed under 
conditions of high concentrations of reagents in order to
OBut OButr
Z-Glu-Leu-D-Leu-Val-Asp-OH + L-CH3 (CH2)10CHCH2CO2NBzl H-Leu-D-Leu-
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65
(60%)








Figure 51. The Preparation of the Octadepsipeptide Precursor to Norsurfactin
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)^ qCHCH2C02NBz1 Z-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leu 
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66
H2/Pd







The Hydrogenolytic Removal of the C- and N- 
Terminal Protecting Groups from Octadepsipeptide 
66.
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maximize the formation of the activated species. If the 
N-terminal amino group of the peptide is left unprotected 
under such conditions, intermolecular reactions take place 
leading to polymeric products, and the yield of intramolec­
ular cyclization product is very low. If, however, the 
activation and cyclization steps are separable then the 
carboxyl group can be activated under conditions of high 
concentrations of reagents while the amino group is protected 
to prevent polymerization. Cyclization may then be accom­
plished by generating the free amino group and allowing
intramolecular substitution to take place under dilute con- 
-3 -4ditions (10 -10 M ) . In this manner the yield of cyclic
product is maximized and the formation of oligomers and 
polymers is minimized. Activated esters have been found to 
give good results in cyclization sequences (Figure 53).
This type of cyclization cannot be applied to the 
synthetic strategy outlined in Chart IV. It is not possible 
to selectively remove the C-terminal p-nitrobenzyl ester on 
intermediate 66^  without disturbing some other portion of the 
molecule as well. Thus the activation and cyclization steps 
cannot be separated in the manner shown in Figure 53. This 
situation is often encountered when protected functional side 
chains appear in the acyclic precursors to cyclic peptides and 
depsipeptides. In these cases, the direct cyclization of 
peptides unprotected at both C- and N-terminal positions must 
be achieved and has often been reported.^-
Ill
DCC
X-(AA) -OH +  HOR .. • ■ -> X-(AA) -OR .n act n act.
H + L -—  L<' >H2 - (AA>- 0Ract. dilution >  (AA)TT
X = acid labile N-terminal protecting group
Figure 53. A General Activated Ester Cyclization Sequence,
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However, separation of the activation and cyclization 
steps can be achieved for these free peptide derivatives under 
appropriate conditions. One example is activation by the 
formation of mixed carbonic anhydrides in a pyridinium chloride 
buffer.'*'1  ^ This allows C-terminal activation while the amino 
group is protonated. Once the formation of the mixed anhydride 
is complete, the activated peptide can be cyclized by the 
addition of an appropriate base in dilute solution. A similar 
procedure for the separation of activation and cyclization 
for free peptides has been developed using Woodward's Reagent 
K.111
Alternatively, the cyclization of free peptides has 
been achieved by carrying out the activation step under con­
ditions of high dilution by using a large excess of the 
activating reagents. In this method the activation and 
cyclization steps are not separated, but the activated acyclic 
peptide is formed only under conditions of high dilution. 
Intermolecular reactions leading to polymeric products are 
minimized.
The cyclization of free peptides by the formation of 
activated succinimido-esters under dilute conditions using 
excess N-hydroxysuccinimide and excess N,N'-dicyclohexyl- 
carbodiimide (see Figure 40) is an example of this tech­
nique. Although the risk of formation of unwanted
side products exists for this method"^®, it was chosen as a 
good method for initial attempts to cyclize octadepsipeptide 
67 since it had been successfully applied to the cyclization
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of a free peptide intermediate leading to isariin.1^
The cyclization of octadepsipeptide 6J7 was attempted 
using this procedure (Figure 54).
_3
A dilute solution of octadepsipeptide 6J7 (1.8 X 10 
M) in a mixed methylene chloride-dimethylformamide solvent 
(34/1, v/v) was treated with 2.7 equivalents of N,N1-dicyclo- 
hexylcarbodiimide and 4.1 equivalents of N-hydroxysuccinimide 
(HOSu). After three days, the desired protected cyclic octa­
depsipeptide 6£, norsurfactin di-tert-butyl ester, was ob­
tained in 41% yield after purification of the crude reaction 
product by column chromatography on silica gel followed by 
high pressure gel permeation chromatography.
Removal of the side chain tert-butyl ester protecting 
groups on the aspartic and glutamic acid residues to afford 
norsurfactin was attempted using anhydrous trifluoroacetic 
acid (TFA) as shown in Figure 55. Norsurfactin (1JL) was ob­
tained in 65% yield after purification by preparative layer 
chromatography on silica gel and high pressure liquid chroma­
tography on C18/Porasil B. The infrared spectrum of the
product was identical to the published spectra for surfac- 
20 22tin. ' The optical rotations of norsurfactin were:
[a]^5 = 27.1° (c 1, CHC13) and [a]^5 = -35.2° (c 1, CH3OH)
27while those reported for surfactin are: taJD = 40° (c 1,
CHC13) and = -39° (c 1, CH3O H ) . ^  The differences in
optical rotations between synthetic norsurfactin and sur­
factin might result from the difference in their structure, 




D-CH3 (CH2 )10CHCH2CO2H H-Glu-Leu-D-Leu-Val-Asp-D-Leu-Leut
I---------------------------- O  1
67
DCC (2.7 eq.) 
HOSu (4.1 eq.) - 







Figure 54. The Formation of the Protected Cyclo octadepsi­
peptide (69) , Norsurfactin di-tert-Butyl Ester.
(65%)
Figure 55. The Preparation of Norsurfactin (11^ ) .
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the presence of impurities in natural surfactin. The ele­
mental analysis for synthetic norsurfactin was determined 
to be: C, 60.77; H, 9.03; N, 9.30 while theoretical values
are calculated as C, 61.09; H, 8.97; N, 9.59 for •
The amino acid ratios of the synthetic compound were found 
to be: Asp, 0.99; Glu, 0.98; Leu, 4.05; Val, 0.94.
Experiments designed to test the biological activity* 
and the chemical purity of synthetic norsurfactin (11) are 
in progress.
Attempted cyclizations leading to a norsurfactin 
diastereomer (derived from model octadepsipeptide 65) are 
also being studied.
*After the completion of this thesis, hemolytic activity 
data on synthetic norsurfactin was obtained. Under the 
conditions reported by Bernheimer and Avigad2®, synthetic 
norsurfactin exhibited hemolytic activity comparable to 




Gas-Liquid Chromatography Analyses (GLC) were per­
formed on a Varian Aerograph Model 90-P gas chromatograph 
coupled to a Sargent Welch Model SRG recorder with Disc 
integrator. A 3% SE-30 on Varaport 30 (80-100 mesh) column 
(5 ft. x 1/4 in.) was used for all analyses in this study. 
Helium was used as a carrier gas at a flow rate of 60 ml/min. 
Retention times and column temperature are indicated for 
each compound.
Infrared Spectra (ir) were recorded on a Perkin- 
Elmer 337 grating spectrophotometer and calibrated using the 
1601.4 and 1028 bands of polystyrene. The spectra of liquids 
were obtained neat, while those of solids were obtained as 
mulls.
Nuclear Magnetic Resonance Spectra (nmr) were ob­
tained on a Jeolco Model JNM-MH 100, 100 MHz nmr. All 100 
MHz spectra are numbered less than 3000. A Varian Model 
A-60 Spectrometer was used to record 60 MHz nmr spectra.
All 60 MHz spectra are numbered greater than 3000. Chemical 
shifts are reported relative to tetramethylsilane. Splitting 
patterns are designated as: s, singlet; d, doublet; t,
triplet; ABq, AB quartet; m, multiplet.
Melting points were obtained using a Thomas-Hoover 
melting point apparatus and are uncorrected.
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Optical Rotations were determined on a Carl Zeiss 
Photoelectric Precision Polarimeter.
Elemental Analyses were performed on an F&M Model 185 
carbon, hydrogen and nitrogen analyzer by Ms. L. Heavner,
Dr. G. Lambert and Ms. D. Cardin at the University of New 
Hampshire.
Amino Acid Analyses were performed on a Beckman 
model 12OC amino acid analyzer.
High Pressure Liquid Chromatography was performed on 
a Waters ALC/GPC-2 02 chromatograph equipped with a model 
6000 delivery system, USK injector and refractive index and 
ultra-violet detection systems.
Thin Layer Chromatography (TLC) was performed on 
silica gel (Adsorb. A) and basic alumina (Adsorb. B) plates 
in the following solvent systems:
A. Chloroform-acetone (80:20)
B. Chloroform-methanol-acetic acid (85: 10:15)
C. Chloroform-acetone (90:10)
D. Ethanol-water (65:35)
E. n-Butanol-acetic acid-water-pyridine (15:3:12:10)
F. Pyridine-acetic acid-water (t0: 30:15)
G. Chloroform-ethanol (80:20)
H. Acetonitrile-water (85:15)
I. Ethyl acetate-acetic acid-water (8 8 :6 :6 )
J. Ethanol-28% ammonia water-water (7:3 : 2 )
K. Methanol
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Compounds were purchased from commercial sources and 
used as received, unless otherwise noted.
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D,L-3-Hydroxytetradecanoic Acid (12). A mixture of 
zinc dust (18.5 g, 0.2 80 mol) and dodecylaldehyde (16) (50.5
g, 0.275 mol) in anhydrous tetrahydrofuran (100 ml) and tri- 
methylborate (100 ml) was cooled to 10°. To this vigorously 
stirred cold mixture ethyl bromoacetate (17) (10 g portion)
was added to initiate the reaction. When the vigorously 
exothermic reaction occurred the mixture was allowed to cool 
to room temperature and a dropwise addition of ethyl bromo­
acetate (total amount, 46.0 g, 0.275 mol) was resumed. When 
addition was completed the mixture was stirred at room temp­
erature for 16 hr. Concentrated ammonium hydroxide ( 6 8  ml) 
and glycerine ( 6 8 ml) were added and stirring was continued 
for 30 min. The mixture was filtered and the filtrate was 
extracted with diethyl ether (3 x 300 ml). The ethereal 
extracts were combined, dried (MgSO^) and concentrated to 
give crude D,L-ethyl-8 ~hydroxytetradecanoate (18J as a yellow 
oil.
A solution of potassium hydroxide (37.0 g) in 95% 
ethanol (400 ml) was added slowly to a stirred solution of 
oil _18 in 95% ethanol (100 ml) . Stirring was continued 
overnight. The resulting mixture was diluted with distilled 
H 2 O (2 £) and washed with diethyl ether (2 x 500 ml). The 
aqueous phase was acidified with 1 0 % I^SO^ and the resulting 
oil was extracted into diethyl ether (2 x 350 ml). The 
ethereal extracts were combined, dried (MgSO^) and concen­
trated to a pale solid. The solid (45 g) was dissolved in 
benzene (150 ml), the hexane (45 0 ml) was added, and upon
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cooling to -15° crystals formed. D,L-3-Hydroxytetradecanoic 
acid (12^ ) was obtained as a white solid, 43.7 g (65%); mp 77-
O  O
78°; lit. mp 78-79°.
Resolution of D,L-B-Hydroxytetradecanoic Acid. To 
a gently boiling solution of D,L- 8 -hydroxytetradecanoic acid 
(12) (30.0 g, 0.123 mol) in anhydrous diethyl ether (325 ml)
was added carefully a solution of (-)-a-methylbenzylamine,
[a] ^ 5 -38.4° (neat),' optical purity 96%,* lit .'*'2 0  [ct] 2 5  -40.1° 
(neat), (14.8 g, 0.122 mol) in anhydrous diethyl ether (90 ml). 
After 12 hr at -15° the precipitated salt was filtered, washed 
well with diethyl ether and dried to give 41.4 g (93%) of the 
amine salt.
The salt was recrystallized from a mixture of anhydrous 
diethyl ether (414 ml) and absolute ethanol (207 ml) by cool­
ing the solution for 6 days at 5°. The salt obtained (15.9 g) 
was recrystallized again from anhydrous diethyl ether (300 ml) 
and absolute ethanol (15 0 ml) by cooling the solution at 5° 
for 10 days to give 3.15 g (15%) of the amine salt. The 
rotation of the 8 -hydroxytetradecanoic acid obtained by
decomposing a small amount of this salt with hydrochloric
25acid as in the procedure described below was: ta]D -14.9°
(c 2, CHCl^), 93% ee. A second crop of amine salt (2.0 g,
25[a]D -14.4, 90% ee) was obtained by cooling the mother 
liquors from prior crystallization and recrystallizing the 
precipitated salt (6 . 8  g) from anhydrous diethyl ether (125 
ml) and absolute ethanol (63 ml).
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The combined salts (5.00 g) were recrystallized from 
anhydrous diethyl ether (60 ml) and absolute ethanol (30 ml) 
by cooling the solution for 24 hr at 5° to give 3.35 g (16%) 
of the amine salt. This salt was shaken with a mixture of 
diethyl ether (100 ml) and 6 N hydrochloric acid (100 ml).
The ethereal layer was separated, washed with distilled E^O 
(50 ml), dried (MgSO^) and concentrated to a white solid.
The solid was recrystallized from benzene (10 ml) by the 
addition of hexane (50 ml) with cooling to give (-)-D-3- 
hydroxytetradecanoic acid, 2.1 g (14.2%) \ mp 74-75°,' [a] 2 5  
-15.4° (c 2, CHC13) (96% ee); lit . 8 2  mp 73-74°; [a] 2 5  -16.0° 
(c 2, CHC13).
(+)-L-0-Hydroxytetradecanoic acid (12_) was resolved 
in a similar fashion using the 3 -hydroxytetradecanoic re­
covered from the resolution of the D-enantiomer and (+)-a- 
methylbenzylamine. The desired L-3-hydroxytetradecanoic acid 
was obtained in 17% yield; mp 74-75°; [a] ^ 5 +15.4° (c 2, 
CHC13), 96% ee.
D,L-tert-Butyl-3-hydroxytetradecanoate (2^ 0) . Di- 
methylformamide dineopentyl acetal (17.5 ml) was added to a 
solution of D,L-3-hydroxytetradecanoic acid (12) (4.4 g, 18
mmol) in anhydrous tert-butyl alcohol with stirring. The 
mixture was heated to 75° under reflux for 20 min. The 
solution was concentrated at 7 0° and the resulting oil was 
dissolved in diethyl ether (7 5 ml) and washed with 1^0 
(2 x 75 ml) , saturated NaHCC>3 solution (2 x 75 ml) , 1^0 
(75 ml) and 10% aqueous citric acid solution (75 ml). The
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solution was then dried (MgSO^) and concentrated to a yellow 
oil (6.12 g).
A sample of this oil (2.0 g) was purified by dry 
column chromatography on a 3 cm x 50 cm column of silica gel 
(Woelm) using benzene as the developing solvent. The product 
was extracted from the silica gel using diethyl ether and the 
extract was concentrated to a colorless oil, 1.2 g (60%). GLC 
analysis showed the oil to be greater than 97% D ,L-tert-butyl- 
g-hydroxytetradecanoate, R.T. 2.25 min (col. temp. 170°).
The retention time was identical to a previously prepared 
sample purified by preparative GLCJ nmr spec, no. 16092 
(CDC13), 6 = 0.8 (t, 3H, CH3), 1.25 (s, 20H, 10 -CH2~), 1.4 
(s, 9H, OBu11) , 2.3 (t, 2H, -CH2-) , 3.6 (s, 1H, -OH), 3.8 (m, 
1H, —<i-H) ; ir spec, no. 20714 (neat) 3450 cm-'*' (OH) , 1725 
(C=0), 1250 (C-H).
Anal. Calcd for cigH 3 6 ° 3 : c » 72.15; H, 12.00.
Found: C, 72.38; H, 12.50.
Benzyloxycarbonyl-L-leucine (21_) . This compound was 
prepared in a manner analogous to that described for benzyl- 
oxycarbonyl-D-leucine (52^ ) later in the experimental. A 
yield of 28.2 g (70%) of a highly viscous clear oil was ob­
tained. TLC: Solv. A, Adsorb. A, 0.78J -15.6° (c
1 I o n c
4.21, abs. EtOH) ; lit. ° [ot] ^  -16.4° (abs. EtOH) .
The Attempted Esterification of Benzyloxycarbonyl-L- 
leucine (21_) with D ,L-tert-Butyl-g-hydroxytetradecanoate (20) . 
Method A . To a stirred solution of benzyloxycarbonyl-L- 
leucine (2_1) (0.87 g, 3.2 mmol) in anhydrous methylene
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chloride (10 ml) at 0° a solution of N,N'-carbonyldiimidazole 
(0.52 g, 3.2 mmol) in anhydrous methylene chloride, was added 
dropwise, over a 15 min period. A solution of D ,L-tert-butyl- 
3-hydroxytetradecanoate (2£) (0.90 g, 3.0 mmol) in anhydrous
methylene chloride (10 ml) was added and stirring was continued 
for 1 hr at 0° followed by 3 days at room temperature. The 
reaction mixture was then concentrated and the resulting oil 
was dissolved in diethyl ether (50 ml). The ethereal solution 
was washed with H20 (20 ml), 10% citric acid solution (20 ml), 
H20 (20 m l), 5% NaHCO^ solution (2 x 20 ml) and H20 (20 ml).
The organic phase was dried (MgSO^) and concentrated to a 
yellow oil, 0.7 9 g. GLC of this oil showed it to be greater 
than 90% D ,L-tert-butyl-g-hydroxytetradecanoate (2_0) .
Method B . The above procedure was repeated using 
tetrahydrofuran as the solvent. The reaction time was ex­
tended to 5 days and the reaction mixture worked up as before. 
Only D,L-tert-butyl-3-hydroxytetradecanoate was recovered from 
the reaction mixture.
Method C . A solution of benzyloxycarbonyl-L-leucine 
(21) (1.43 g, 5.4 mmol) in a mixture of anhydrous tetrahydro­
furan (2.5 ml) and anhydrous pyridine (2.5 ml) was cooled to 
-15°. Benzenesulfonyl chloride (0.97 g, 5.4 mmol) was then 
added dropwise, with stirring, over 3 min. The resulting 
solution was stirred at -15° for 25 min. The solution was 
then cooled to -30° and a solution of D,L-tert-butyl-3~ 
hydroxytetradecanoate (20J (1.15 g, 3.7 mmol) in anhydrous
tetrahydrofuran (2 ml) was added. Stirring was continued at
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-30° for 1 hr, at -10° for 1 hr, at 5° for 10 hr and at 25° 
for 2 hr. The reaction mixture was then poured into IN HC1 
(15 ml) and then extracted with ethyl acetate (2 x 25 m l).
The ethyl acetate extracts were combined and washed with 10% 
citric acid solution (15 m l), 5% NaHC03 solution (2 x 20 ml) 
and H20 (20 ml). The organic phase was dried (MgS04) and 
concentrated to a dark brown oil, 2.1 g. GLC analysis of 
this oil showed it to be primarily D,L-tert-butyl-8-hydroxy- 
tetradecanoate (2£) plus some unidentified volatile components. 
TLC (Solv. B, adsorb. B) indicated only starting tert-butyl 
ester (2J)) was present.
The Esterification of Benzyloxycarbonylglycine (23) 
with D,L-tert-Butyl-B-hydroxytetradecanoate (20). This 
compound was prepared by Method C as described for the 
attempted preparation of compound (2^ 2) . After the initial 
workup the crude product was purified by preparative layer 
chromatography on silica gel using chloroform-acetone (97/3, 
v/v) as the developing solvent. Compound 2_4 was obtained as 
a clear oil, 0.36 g (75%); nmr spec, no. 1386 (CDC13) 6 =
0.9 (t, 3H, CH3~), 1.3 (s, 20H, -CH2~), 1.5 (s, 9H, t-butyl-),
2.5 (d, 2H, -CH2~), 3.9 (d, 2H, -CH2~ of Gly), 5.2 (s, 2H, 
-CH2-Ph), 5.3 (m, 1H, “C“H) , 5.9 (m, 1H, -NH-), 7.4 (s, 5H,
Ph-) .
Anal. Calcd for C 28H45N 1°6: C ' ^8.55; h , 9.15;
N, 2.85. Found: C, 68.49; H, 9.15; N, 2.76.
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D,L-Methyl-g-hydroxytetradecanoate (25). A. Di­
me thy If ormamide dineopentyl acetal (20 ml) was added to a 
solution of D,L-B-hydroxytetradecanoic acid (12) (5.0 g, 20
mmol) in anhydrous methanol (100 ml) with stirring. The 
solution was refluxed for 2 0 min and then concentrated to a 
yellow oil to which 1^0 (200 ml) was added. The resulting 
suspension was extracted into ethyl acetate (2 x 150 ml) and 
the combined extracts were washed successively with ^ 0  (2 x 
100 ml), saturated NaHCO^ solution (2 x 100 ml) and saturated 
NaCl (50 ml). The organic phase was dried (MgSO^) and con­
centrated to a yellow oil. GLC analysis of this oil showed 
it to be 65% of the desired D,L-methyl-3-hydroxytetradecanoate 
(2_5) , R.T. 2.6 min. The oil was dissolved in pentane (15 ml) 
and the solution was cooled to -15° for 2 days. The crystal­
line solid was collected and dried to give 0.90 g (17%) of 
pure D,L-methyl-3-hydroxytetradecanoate, mp 33-35°.
Method B . An ethereal solution of diazomethane was
prepared from p-tolylsulphonyl-methyl-nitrosamide (21.5 g,
1170.1 mol) according to the procedure of Vogel. The ice-
cold diazomethane solution was added slowly with stirring to 
an ice-cold suspension of D,L-g-hydroxytetradecanoic acid 
(12) (12.15 g, 50 mmol) in anhydrous diethyl ether (150 ml)
until the yellow color of the solution persisted. A few 
drops of acetic acid were added to decompose any excess 
diazomethane and the mixture was concentrated to a yellow 
oil. This oil was dissolved in diethyl ether (75 ml) and 
washed with saturated NaHCO^ solution (3 x 25 m l). The
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organic phase was dried (MgSO^) and concentrated to a color­
less oil which solidified upon standing to give D,L-methyl- 
B-hydroxytetradecanoate (25^ ) as a crystalline solid, 12.5 g 
(98%), mp 34-35°. GLC analysis showed the sample to be pure, 
R.T. 2.6 min (col. temp. 170°).
Anal. Calcd for ci5 H 3 0 ° 2 : C ' 69.80; H, 11.62.
Found: C, 69.85; H, 11.71.
The Attempted Esterification of Benzyloxycarbonyl-L- 
leucine (21) with D,L-Methyl-B-hydroxytetradecanoate (25). 
Method A . A solution of benzyloxycarbonyl-L-leucine (21) 
(1.46 g, 5.5 mmol) in a mixture of anhydrous tetrahydrofuran 
(4 ml) and anhydrous pyridine (4 ml) was cooled to -15°. 
Benzenesulfonyl chloride (0.98 g, 5.5 mmol) was then added 
dropwise, with stirring, over a 3 min period. Stirring was 
continued at -15° for 30 min and then the mixture was cooled 
to -30°. D ,L-Methyl-8 -hydroxytetradecanoate (25_) (1.0 g,
3.75 mmol) was added and stirring was continued at -30° for 
1 hr, at -15° for 1 hr, at 0° for 18 hr, and at room tempera­
ture for 24 hr. The reaction mixture was then poured into 
3N HC1 (30 ml) with stirring and the resulting mixture was 
extracted into ethyl acetate (2 x 4 0 ml). The combined 
estracts were washed successively with H20 (2 x 50 ml), 
saturated NaHCO^ solution (2 x 50 ml) and 3N HC1 (50 ml).
The organic phase was dried (MgSC>4) and concentrated to a 
colorless oil, 1.69 g. A sample of this oil (0.40 g) was 
purified by preparative layer chromatography on silica gel 
using 95% ethanol-H20 (60/40, v/v) as the developing solvent.
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Compound 2£ was obtained as a crude oil, 0.11 g (25%).
Anal. Calcd for C29H4iNi°6: C ' 68*9°/' H * 9.37;
N, 2.77. Found: C, 67.67; H, 9.78; N, 2.20.
Method B . To a stirred solution of benzyloxycarbonyl- 
L-leucine (2_1) (1.55 g, 5.85 mmol) in anhydrous methylene
chloride (25 ml) at 0° was added a solution of N,N'-carbonyl- 
diimidazole (0.95 g, 5.85 mmol) in anhydrous methylene 
chloride (15 ml), dropwise over a 30 min period. A solution 
of D,L-methyl-g-hydroxytetradecanoate (2_5) (1.5 g, 5.85 mmol)
in anhydrous methylene chloride (10 ml) was then added. The 
reaction mixture was stirred at 0° for 1 hr and then at room 
temperature for 10 days. It was then concentrated and the 
resulting brown oil was dissolved in diethyl ether (50 ml) and 
was washed successively with H20 (2 x 50 ml), 10% citric acid 
solution (2 x 50 ml), saturated NaHCO^ solution (2 x 50 ml) 
and H20 (50 ml). The organic phase was dried (MgSO^) and 
concentrated to a yellow oil (2.36 g) . This oil was dissolved 
in pentane (35 ml) and cooled at -15° for 24 hr. The D,L- 
methyl-g-hydroxytetradecanoate which precipitated was 
collected by filtration (0.13 g, mp 34-36°), and the filtrate 
was concentrated to a yellow oil. A sample of this oil (1.14 
g) was purified by dry column chromatography on a 3.0 cm x 
50 cm column of silica gel (Woelm) using 95% ethanol-H20 
(60/40, v/v) as the developing solvent. The product was ex­
tracted from the silica gel using ethyl acetate and the ex­
tract was concentrated to give crude compound 26^  as a yellow 
oil, 0.71 g (40%).
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Anal. Calcd for C ^ H ^ N O g :  C, 68.90; H, 9.37;
N, 2.77. Found: C, 69.34; H, 9.86; N, 3.17.
The Esterification of Benzyloxycarbonylglycine (23) 
with D,L-Methyl-g-hydroxytetradecanoate (25). Method A .
The esterification was carried out in a manner analogous to 
the esterif ication of benzyloxycarbonyl-L-leucine (2_1) with 
compound 25^  (Method A) . After work up of the reaction mix­
ture, 1.60 g of a colorless oil was obtained. This oil was 
dissolved in pentane (25 ml) and the solution was cooled to 
-15° for 24 hr. The precipitated solid was collected and 
dried to afford compound 21_, 1.18 g (70%); mp 43-44°; nmr 
spec, no. 1428 (CDC13) 6 = 0.95 (t, 3H, CH3~), 1.15 (s, 20H, 
-CH2-), 2.6 (d, 2H, -CH2~) , 3.7 (s, 3H, -OC^), 4.0 (d, 2H, 
-CH2-NH~), 5.25 (s, 2H, -CH2-Ph), 5.4 (m, 2H, -C-H, 3J-H),
7.5 (s, 5H, Ph-).
Anal. Calcd for C25H39N06 : C ' ^7.40; H, 8.75; N,
3.12. Found: C, 67.61; H, 8.82; N, 3.16.
Method B . A procedure was used analogous to the 
procedure used for the esterification of benzyloxycarbonyl- 
L-leucine (2]L) with compound 25^  (Method B) . After work-up 
of the reaction mixture, 2.25 g of a yellow oil was obtained. 
This oil was dissolved in pentane (25 ml) and the solution 
was cooled to -15° for 24 hr. The precipitated solid was 
collected and dried to afford compound 2_7, 1.46 g, mp 41.5- 
42.5°. A second crop of solid was obtained by concentrating 
and cooling the mother liquors, 0.18 g, mp 42-43°. A total 
yield of 1.64 g (62%) of compound 27 was obtained.
130
D,L-Methyl-6-hydroxybutyrate (28j. An ethereal
solution of diazomethane was prepared from p-tolylsulfonyl-
methyl-nitrosamide (43.0 g, 0.2 mmol) according to the
117procedure of Vogel. The ice-cold diazomethane solution
was added slowly, with stirring, to an ice-cold solution of 
D,L-methyl-3-hydroxybutyric acid (11.0 g, 0.105 mol) in an­
hydrous diethyl ether (100 ml) until the yellow color of 
solution persisted. A few drops of acetic acid were added 
to decompose any excess diazomethane and the mixture was 
concentrated to a yellow oil. The oil was distilled and the 
fraction boiling between 75-78° (25 mm) was collected to give
6.76 g (50%) of D ,L-methyl-g-hydroxybutyrate (2J3) . GLC 
analysis of the product showed it to be primarily a single 
component, R.T. 1.0 min (col. temp. 75°); nmr spec, no. 1331 
(CDC13 ) 6 = 1.26 (d, 3H, CH^-), 2.60 (d, 2H, -CH2~), 3.84
(s, 3H, -OCH3), 4.34 (m, 1H, -<p-H) , 4.78 (s, 1H, -OH).
The Esterification of Benzyloxycarbonylglycine (23) 
with D,L-Methyl-6-hydroxybutyrate (2£). The esterification
was carried out in a manner analogous to that described for 
the esterif ication of benzyloxycarbonyl-L-leucine (2_1) with 
compound 25^  (Method A) . After workup of the reaction mix­
ture a yellow oil was obtained, 3.7 8 g. GLC analysis of this
oil showed that it contained 74% of compound 29^  corresponding 
to a 60% yield, R.T. 11 min (col. temp. 170°). A sample of 
this oil was purified by preparative layer chromatography on 
silica gel using chloroform as the developing solvent; nmr 
spec, no. 1339 (CDC13) 6 = 1.2 (d, 3H, CH3~), 2.5 (t, 2H,
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-CH2-), 3.6 (s, 3H, -0-CH3), 3.9 (d, 2H, -CH2-NH-), 5.2 (s,
2H, -CH2-Ph) , 5.4 (m, 1H, -<J:-H) , 6.0 (d, 1H, -NH-) , 7.5 (s,
5H, Ph-).
Anal. Calcd for ci5 Hi 9 NOg : C ' 58.20; H, 6.20; N,
4.53. Found: C, 58.02; H, 6.24; N, 4.40.
The Esterification of Benzyloxycarbonyl-L-alanine 
(30) with D,L-Methyl-8-hydroxybutyrate (2^ 8) . The esterifi­
cation was carried out in a manner analogous to that des­
cribed for the esterification of benzyloxycarbonyl-L-leucine 
(21) with compound 2jj (Method A) . After workup of the reac­
tion mixture a yellow oil was obtained, 3.06 g. GLC analysis 
of this oil showed that it contained 84% of compound 3JL cor­
responding to a 57% yield, R.T. 3 min (col. temp. 200°). A 
sample of this oil was purified by preparative layer chrom­
atography on silica gel using chloroform as the developing 
solvent; nmr spec, no. 1338 (CDCl^) 6 = 1.2 (d, 3H, CH3~),
1.4 (d, 3H, CH3-), 2.6 (t, 2H, -CH2~), 3.6 (s, 3H, -0-CH3),
4.2 (m, 1H, -CH-NH ), 5.2 (s, 2H, -CH_2-Ph) , 5.4 (m, 1H,
-C-H.) , 6.1 (d, 1H, -NH-) , 7.5 (s, 5H, Ph-) .
Anal. Calcd for cigH21N06 : C ' 5^.42; H ' 6.54;
N , 4.34. Found: C, 59.88; H, 6.58; N, 4.19.
The Esterification of Benzyloxycarbonyl-L-leucine 
(21) with D,L-Methyl-g-hydroxybutyrate (2^) . The esterifi­
cation was carried out in a manner analogous to that described 
for the esterification of benzyloxycarbonyl-L-leucine (21) 
with compound 25^  (Method A) . After workup of the reaction 
mixture a yellow oil was obtained, 2.3 0 g. GLC analysis of
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this oil showed that it contained 52% of compound 32_ cor­
responding to a 34% yield, R.T. 17 min (col. temp. 175°).
A sample of this oil was purified by preparative layer 
chromatography on silica gel using chloroform as the devel­
oping solvent; nmr spec no. 1368 (CDC13) 6 = 1.0 (d, 6H,
2CH3-), 1.2 (d, 3H, CH3-), 1.6 (m, 2H, -CU2~ ) , 3.7 (s, 3H, 
-0-CH3), 4.2 (m, 1H, ~^-H), 5.2 (s, 2H, -CH2~Ph), 5.4 (q,
1H, -CH-NH-), 5.9 (d, 1H, -NH-), 7.5 (s, 5H, Ph-).
Anal. Calcd for C19H2?N06 : C, 62.55; H, 7.41; N,
3.84. Found: C, 62.81; H, 7.42; N, 3.75.
D-p-Nitrobenzyl-B-hydroxytetradecanoate (D-34).
(-)-6-Hydroxytetradecanoic acid (9.66 g, 0.04 mol), triethyl 
amine (4.0 g, 0.04 mol) and p-nitrobenzyl chloride (6.7 g, 
0.04 mol) were dissolved in distilled ethyl acetate (100 ml) 
and stirred at reflux for 3 days. The precipitated tri- 
ethylamine hydrochloride was removed by filtration and the 
filtrate was stirred with saturated NaCl solution (150 m l). 
The sodium salt of the unreacted hydroxyacid precipitated 
immediately and it was removed by filtration. The residue 
was washed with a small volume of acetone followed by di­
ethyl ether. The filtrate and washings were combined and 
the organic layer was separated and washed successively with 
saturated NaHCC>3 solution (2 x 50 ml) , distilled H20 (50 ml) 
10% citric acid solution (50 ml) and saturated NaCl solution 
(50 ml). The organic phase was dried (MgSC>4 ) and evaporated 
to a yellow oil which was immediately dissolved in pentane 
(250 ml) and allowed to crystallize at 5° for 24 hr. The
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crystalline solid was filtered and allowed to dry, giving 
10.37 g of a pale yellow solid, xnp 55-56°. A second crop of 
1.48 g (mp 54-56°) was obtained from the mother liquor by 
concentrating and cooling. The two crops were combined and 
recrystallized from ethyl acetate-pentane to give 11.4 g
25(77%) of a cream colored crystalline s o l i d m p  55-56°,* [a]D 
-12.5° (c 2, CHC13) .
Anal. Calcd for C 2 2 H 3 3 N0 5 : C, 66.47; H, 8.76;
N, 3.69. Found: C, 66.64; H, 8.51; N, 3.74.
The sodium salt of the unreacted 6-hydroxy acid iso­
lated during the preparation of 3_£ was shaken with a mixture 
of 3N HC1 (50 ml) and diethyl ether (50 ml). The NaHCO^ 
washings from the workup of 34^  were combined, acidified with 
3N HC1 and extracted into diethyl ether (50 ml). The 
ethereal phases were combined, dried (MgSO^) and evaporated 
to a white solid which was recrystallized from a minimum 
volume of hot benzene by adding pentane and cooling to -15°. 
The precipitated D-6-hydroxytetradecanoic acid was collected 
and dried to give 1.63 g (17%), -15.5 (c 2, CHCl^).
L-p-Nitrobenzyl-6-hydroxytetradecanoate (L-34). 
Compound L-34 was prepared by the same procedure used for 
D-34. A total yield of 4.6 g (62%) was obtained (mp 54.5- 
55.5), [ct]^5 11.1° (c 2, CHC13).
Anal. Calcd for C^H^NO,.: C, 66.47; H, 8.76;
N, 3.69. Found: C, 66.84; H, 8.91; N, 3.71.
L-6-Hydroxytetradecanoic acid, 1.1 g (23%) was 
recovered during the workup procedure.
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tert-Butoxycarbonyl-D-leucine Monohydrate (3_5) .
9 3
This compound was prepared by the procedure of Weinstein 
as in the preparation of tert-butoxycarbonyl-L-leucine mono­
hydrate (37^, (see following description). A yield of 26.2 g 
(92%) of the crystalline monohydrate was obtained? mp 84-86°;
[a]p5 24. 8° (c 1, HOAc) . TLC: Solv. A, Adsorb A, Rf 0.83*,
lit.119 mp 86-87°, [ctl^5 25.3° (c 1, HOAc).
tert-Butoxycarbonyl-leucine Monohydrate (31_) . A 
mixture of leucine (26.3 g, 0.20 mol) and 1,1,3,3-tetramethyl- 
guanidine (46.0 g, 0.40 mol) in dimethylformamide (500 ml) 
was cooled to 0° in an ice bath. To this cold stirred mix­
ture was added tert-butylazidoformate (43.0 g, 0.30 mol) 
dropwise over a period of 3 0 min. The mixture was stirred 
first at 0° for 1 hr and then at room temperature for 3 days.
A small amount of insoluble material was filtered and the
filtrate was concentrated in vacuo (2 mm). The resulting oil 
was stirred with 20% citric acid solution (200 ml) and ethyl 
acetate (450 ml). The ethyl acetate phase was separated and 
the aqueous phase was extracted with ethyl acetate (2 x 50 ml). 
The ethyl acetate phases were combined and washed with dis­
tilled H 2 O (3 x 75 ml) and saturated NaCl solution (50 ml).
The organic phase was dried (MgSO^) and concentrated to a 
clear oil. The crystalline monohydrate formed readily upon 
the addition of a few ml of distilled H20 and was recrys­
tallized from hot methylene chloride by the addition of 
pentane and cooling to give 42.3 g (85%) of a white crys­
talline solid,* mp 83.5-85.5°; [ ot ] -24.9° (c 1, HOAc);
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TLC: Solv. A, Adsorb. A, Rf 0.81*, lit.119 mp 84°, ta]^5
-24° (c 1, HOAc).
The Esterification of tert-Butoxycarbonyl-D-leucine 
(35) with L-p-Nitrobenzyl-B-hydroxytetradecanoate (L-34). 
Method A . A solution of tert-butoxycarbonyl-D-leucine (35) 
(7.0 g, 2.9 mmol) in diethyl ether (50 ml) was dried over 
anhydrous MgSO^ for 3 hr and then over anhydrous CaSO^ for 3 
hr. The solution was concentrated to a clear oil which was 
stored in vacuo over for several hours.
A solution of this oil in anhydrous methylene chloride 
(50 ml) was cooled to 0° and a solution of N,N'-carbonyldi- 
imidazole (4.7 g, 2.9 mmol) in anhydrous methylene chloride 
(25 ml) was added dropwise with stirring over a 30 min period. 
A solution of L-p-nitrobenzyl-ft-hydroxytetradecanoate (L-34) 
(3.8 g, 1.0 mmol) in anhydrous methylene chloride (25 ml) 
was added and stirring was continued for 1 hr at 0° and then 
for 7 days at room temperature.
The solution was then concentrated and the oily resi­
due was dissolved in diethyl ether (100 ml) and washed 
successively with distilled H 2 O (2 x 100 ml), saturated 
NaHCO^ solution (2 x 75 m l ) , distilled H 2 O (100 m l), 10% 
citric acid solution (2 x 75 ml) and distilled H20 (50 ml).
The ethereal phase was then stirred with saturated NaHCO^ 
solution (100 ml) overnight to remove the excess BOC-D- 
leucine (3_5) . The organic phase was dried (MgSO^) and con­
centrated to an oil which was further purified by filtration 
through a 3.5 x 13 cm column of silica gel using chloroform- 
acetone (80/20, v/v) as the eluant (250 ml collected). The
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eluate was concentrated to a colorless oil, 5.27 g (90%); TLC:
Solv. A, Adsorb. A, 0.83; Solv. A, Adsorb. B, R^ 0.73; nmr
spec, no. 16478 (CDC13) 6 = 0.9 (d, 9H, CH3~), 1.2-1.4 (2s,
m, 32-33H, CH3-,-CH2~, -C-H), 2.5 (d, 2H, -CH2-), 4.0 (m, 1H,
-6-li) , 5.0 (m, 3H, -C-H, -CH -AR) , 7.5 (ABq, 4H, AR-) ; [a]^5
I I u
6.7° (c 2.5, CHC13).
Anal. Calcd for C32H52N2°8: C ' H ' 8*84'"
N, 4.73. Found: C, 65.33; H, 8.89; N, 4.81.
Method B . The same procedure was used as in method
A with the following modifications; the reaction was run in
anhydrous tetrahydrofuran solvent and was catalyzed by the
addition of 2.5 ml of a solution of sodium (1.0 g) and
imidazole (1.0 g) in anhydrous tetrahydrofuran (15 ml). The
catalyst solution was added after the addition of compound
L-34. The time of reaction was shortened to 3 days and work-
25up as m  A gave a 97% yield of compound 36_, [«]D 7.3° (c 2,
c h c i 3).
The Esterification of tert-Butoxycarbonyl-L-leucine 
(37) with D-p-Nitrobenzyl-B-hydroxytetradecanoate (D-34).
The same procedure was used as was described for the prepara­
tion of compound 3J5 (Method A) using tert-butoxycarbonyl-L- 
leucine monohydrate (37_) (22.4 g, 90 mmol) and D-34 (11.0 g,
29 mmol). The reaction was allowed to proceed for 5 days 
and upon workup gave compound 3^, 13.0 g (76%); TLC: Solv.
C, Adsorb. A, R^ 0.91; Solv. C, Adsorb. B, R^ 0.94; nmr 
spec no. 16630 (CDC13) 6 = 0.9 (d, 9H, C ^ - )  , 1.2-1.4 (2s,
m, 32H, CH3-, - CHtj- , -C-H) , 2.6 (d, 2H, -CI3 2 -) , 4.2 (m,
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1H, -t-H), 4.8-5.1 (s, m, 4H, -CH„-AR, -N-H, -fc-H), 7.6 (ABq,Z |
4H, AR); [a]^5 -7.8°.
Anal. Calcd for C ^ H ^ N ^ :  C, 64.85; H, 8.84;
N, 4.73. Found: C, 64.94; H, 9.09; N, 4.85.
The Preparation of Didepsipeptide 39^ . The same pro­
cedure was used as was used for the preparation of compound 
40 (see following description). A yield of 3.8 g (92%) of 
compound 3j) was obtained, TLC; Solv. B, Adsorb. A, R^ 0.47. 
Compound 22. was use<  ^without further purification for the 
preparation of compound 42.
The Preparation of Didepsipeptide 40^ A solution of
38, (12.0 g, 20.3 mmol) and boron trifluoride diethyl ether-
ate (8.14 ml, 61.0 mmol) in glacial acetic acid (150 ml) was 
stirred at room temperature for 3 0 min. The solution was 
then poured into 20% sodium acetate solution (800 ml) and 
solid NaHCOg was added until the mixture became basic (pH 
8-9). The resulting oil was extracted into diethyl ether 
(3 x 250 ml) and the ethereal phases were combined and washed 
with distilled H20 (2 x 500 ml). The ethereal solution was 
dried(MgSO^), decolorized (Norite A) and concentrated to a 
yellow oil (10.0 g, 100%). This oil was purified by dry 
column chromatography on three 3.5 x 35 cm silica gel (Woelm) 
columns using chloroform-methanol-acetic acid (85:10:5) as 
the developing solvent. The desired compound was extracted 
from the silica gel with ethyl acetate (200 ml per column). 
The ethyl acetate extracts were combined and concentrated 
to a volume of 100 ml and were washed with saturated NaHCO^ 
solution (4 x 50 ml) and distilled H20 (50 ml). The organic
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phase was dried (MgSO^) and concentrated to a yellow oil,
9.3 g (92%); TLC: Solv. B, Adsorb. A, 0.61; nmr spec, no.
16630 (CDC13) 6 = 0.90 (d, 9H, CH3~), 1.1-1.4 (s, m. 23H,
i I
-CH2-, , 2.6 (d, 2H, -CH2~) , 3.3 (m, 1H, -C-H) , 4.8-5.1
(s, m, 3H, -CH2-AR, -C-H), 7.5 (ABq, 4H, AR) ; [ ot ] -0.51°
(c 1.7, CHC13).
Anal. Calcd for C27H44N2C>6 : C, 65.82; H, 9.00;
N, 5.69. Found: C, 65.90; H, 9.00; N, 5.85.
The Preparation of Tridepsipeptide £2. A solution 
of tert-butoxycarbonyl-D-leucine monohydrate (37), (4.66 g,
18.7 mmol) in anhydrous THF (100 ml) was dried over anhydrous 
MgS04 for 4 hr. The MgSC>4 was filtered off and the filtrate 
was added to a solution of 3_9 (9.2 g, 18.7 mmol) and 1- 
hydroxybenzotriazole monohydrate (5.75 g, 37.4 mmol) in an­
hydrous THF (100 ml). The resulting solution was cooled to 
0° in an ice bath and then DCC (3.82 g, 19.0 mol) was added 
and the mixture was stirred at 0° for 1 hr, and then at room 
temperature for 2 hr. The precipitated DCU was filtered and 
washed well with THF. The filtrate and washings were com­
bined and concentrated to a yellow oil which was dissolved 
in ethyl acetate (100 ml). The ethyl acetate solution was 
filtered to remove additional DCU and washed with distilled 
H20 (2 x 100 ml) , saturated NaHCC>3 solution (2 x 100 ml) ,
10% citric acid solution (100 m l ) , distilled H20 (100 ml) 
and saturated NaCl solution (50 ml). The solution was 
dried (MgS04 ), decolorized (Norite-A), and concentrated to 
a volume of 25 ml. The oily solution was filtered through
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a 4.5 x 15 cm column of basic alumina using ethyl acetate 
as the eluant (600 ml collected). The ethyl acetate was 
concentrated to a pale yellow oil, 13.2 g. The oil was dis­
solved in a mixture of chloroform-acetone (80:20, 15 ml) and 
filtered through a 4.5 x 15 cm column of silica gel (40-140 
mesh) using chloroform-acetone (80:20) as the eluent (500 ml 
collected). The eluate was concentrated to a pale-yellow, 
viscous oil, 13.0 g (98%); TLC: Solv. A, Adsorb. B, Rf
0.89; [a]^5 0.3° (c 0.55, CHC13).
Anal. Calcd for C 3gH63N3Og : C, 64.65; H, 9.00;
N, 5.95. Found: C, 64.67; H, 9.22; N, 6.00.
The Preparation of Tridepsipeptide 4_3. The same 
procedure was employed as was used for the preparation of 
compound 42^  using tert-butoxycarbonyl-D-leucine monohydrate 
(3.4 g, 13.6 mmol) and compound 39^  (6.6 g, 13.5 mmol).
Compound 43^  was obtained as a colorless oil, 9.2 g (97%),'
TLC: Solv. C, Adsorb. A, Rf 0.60; [ ot ] -9.9° (c 2, CHC13).
Anal. Calcd for C3gH63N3O g : C, 64.65; H, 9.00;
N, 5.95. Found: C, 64.74; H, 9.31; N, 5.95.
The Preparation of Tridepsipeptide 44_. A solution 
of compound 42, (1.5 g, 2.1 mmol) and boron trifluoride diethyl 
etherate (0.84 m, 6.3 mmol) in glacial acetic acid (15 ml) 
was stirred for 2 0 min at room temperature. The solution was
poured into 20% sodium acetate solution (15 0 ml) and solid
NaHCC>3 was added until the mixture became basic (pH 8-9) .
The resulting oil was extracted into diethyl ether (3 x 75 
ml) and the ethereal phases were combined, washed with dis-
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tilled ^ O  (2 x 150 m l), dried (MgSO^) and concentrated to a
pale yellow oil, 1.19 g (93%); TLC: Solv. B, Adsorb. A,
0.63; Solv. B, Adsorb. A, Rf 0.55; [ ot ] -0.5° (c 3.01, CHC13).
Anal. Calcd for C33H55N 307 : C, 65.42; H, 9.15;
N, 6.95. Found: C, 65.21; H, 9.12; N, 6.77.
The Preparation of Tridepsipeptide 45^ . The same 
procedure was employed as was used for the preparation of 
compound £4 but using compound 4_3 (2.0 g, 2.84 mmol) in 
place of 42^ . Compound 4-4 was obtained as a pale-yellow oil, 
1.61 g (94%); TLC: Solv. B, Adsorb. A, Rf0.78; [a]^5 0.91°
(c 2, CHC13 ).
Anal. Calcd for C33H55N 3C>7 : C, 65.42; H, 9.15;
N, 6.94. Found: C, 65.51; H, 9.16; N, 6.90.
Benzyloxycarbonyl(B-tert-butyl)aspartate (4j6) .
Compound 46^  was prepared by the procedure of Schwyzer and
103Dietrich and isolated as its dicyclohexylamine salt; mp 
122.5-123°; [ct]^7 6.10° (c 2, glacial HOAc); lit.103 mp 125-
126°; [a]35 5.5° (c 1.72, 90% HOAc).
8-tert-Butyl Aspartate (£7J . Benzyloxycarbonyl-(8-
tert-butyl)-aspartate dicyclohexylamine salt (46/DCHA), (2.5
g, 5.0 mmol) was stirred in a mixture of ethyl acetate (75 
ml) and 10% citric acid solution (75 ml) for 30 min. The 
ethyl acetate phase was separated and the aqueous phase was 
extracted with ethyl-acetate (50 ml). The ethyl acetate 
phase and extracts were combined, dried (MgSO^) and concen­
trated to a clear oil.
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Palladium on carbon catalyst (5%, 0.4 g) was added to 
a degassed (N2) solution of the above oil in methanol (50 ml) 
and glacial acetic acid (5 drops). The mixture was degassed 
again (N2) and hydrogenated at 10 psi for 3 hr. The catalyst 
was removed by filtration through Celite and the filtrate was 
concentrated to a white solid. The solid was taken up in 
methanol (2 0 ml) and precipitated (as a gel) by the addition 
of anhydrous diethyl ether. The gel was filtered and dried 
in vacuo to give 0.45 g of a white solid. An additional 0.36 
g was obtained from the mother liquors by concentrating them 
to a clear oil, adding diethyl ether to precipitate a gel 
and then drying in vacuo. Both solids were combined, tritur­
ated well with diethyl ether, and dried in vacuo overnight 
to give 0.80 g (84%) of a white solid; mp 188-190°d; TLC:
Solv. B, Adsorb. A, Rf 0.15 [a]^5 8.1° (c 1.0, 90% acetic 
acid); lit.1(^ 5 mp 189-190°d, [ot]^ 8.5° (c 1, 90% acetic acid).
o-Nitrophenylsulfenyl(8-tert-butyl)aspartate Dicyclo­
hexylamine Salt (4J3) . To a vigorously stirred solution of
8-tert-butyl aspartate (4_7) (1.30 g, 6.8 mmol) in dioxane
(17 ml) and 2N NaOH (3.4 ml) was slowly added o-nitrophenyl- 
sulfenyl chloride (£8) (1.42 g, 7.5 mmol) over a period of
15 min as 2N NaOH (3.4 ml) was added to maintain the pH be­
tween 8 and 10. Distilled H20 (7 5 ml) was added and the 
mixture was filtered. The filtrate was acidified to pH 5-6 
by the addition of 0.5N H2SO^. The resulting oil was extracted 
into diethyl ether (3 x 75 ml). The ethereal phase was dried 
(MgSO^) and concentrated to a volume of approximately 50 ml.
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Dicyclohexylamine (1.25 ml) was added and the solution was 
placed in a freezer at -15° overnight. The precipitated 
salt was collected and dried, 1.63 g, mp 158-160°. An addi­
tional 0.74 g (mp 160-161°) was obtained from the mother 
liquors by concentrating and cooling. The combined solids 
were recrystallized from a minimum volume of methanol by the 
addition of diethyl ether with concentrating and cooling. A 
yield of 2.15 g (60%) of a bright yellow crystalline solid 
was obtained; mp 162-163°; TLC: Solv. D, Adsorb. A, Rf 0.95;
[a]^5 -51.7° (c 2, CHC13).
Anal. Calcd for c 26H4lN3°6S: C ' 59*63' H ' 7 -89;
N, 8.02. Found: C, 59.74; H, 7.76; N, 8.09.
The Preparation of Tetradepsipeptide 51. o-Nitro-
phenylsulfenyl(6-tert-butyl)aspartate dicyclohexylamine salt
(49) (1.02 g, 1.95 mmol) was shaken with a mixture of diethyl-
ether (50 ml) and 10% citric acid solution (75 ml). The
ethereal phase was separated, dried (MgSO^) and concentrated
to a bright yellow oil.
A solution of this oil, compound !50, (1.18 g, 1.95
mmol) and 1-hydroxybenzotriazole monohydrate (0.60 g, 2.90
mmol) in anhydrous THF (25 ml) was cooled to 0° in an ice
bath and DCC (0.41 g, 2.0 mmol) was added. The mixture was
stirred first at 0° for 1 hr and then at room temperature for
2 hr. The precipitated DCU was filtered and washed well with
THF. The filtrate and washings were combined and concentrated
to a yellow oil which was dissolved in ethyl acetate (100 ml).
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The ethyl acetate solution was washed successively with dis­
tilled 1^0 (2 x 50 m l ) , saturated NaHCO^ solution (3 x 50 ml), 
10% citric acid solution (50 ml), distilled H20 (50 ml) and 
saturated NaCl solution (50 ml). The organic phase was dried 
(MgS04 ) and concentrated to a yellow oil. A solution of this 
oil in ethyl acetate (5 ml) was filtered through a 12 x 3.5 cm 
column of basic alumina using ethyl acetate as the eluant (200 
ml collected). The ethyl acetate eluate was concentrated to a 
viscous oil which was dried in vacuo at 0.1 mm Hg at 60° 
overnight to give 1.25 g (70%) of a bright yellow glassy 
solid,* TLC: Solv. A, Adsorb. A, 0.95; Solv. B, Adsorb. A,
Rf 0.91; [a]p5 -34.4° (c 0.5, CHC13).
Anal. Calcd for C , _,Hn n N^ O., „S: C, 60.69; H, 7.69;
-----  4 / 11 b led
N , 7.53. Found: C, 60.50; H, 7.86; N, 7.38.
Benzyloxycarbonyl-D-leucine (52J. To a vigorously 
stirred mixture of D-leucine (25.0 g, 0.19 mol) and NaHCO^ 
(36.4 g, 0.43 mol) in distilled H20 (250 ml) was added benzyl­
oxycarbonyl chloride (35.0 g, 0.206 mol) in 5 portions over 
3 0 min. The mixture was stirred for 3 hr and the remaining 
insoluble material was removed by filtration. The solution 
was washed with diethyl ether (2 x 100 ml) and the aqueous 
phase was acidified to pH 5 by the addition of 6N HCl with 
stirring and cooling. The resulting oil was extracted into 
diethyl ether (3 x 2 00 ml) and the ethereal phases were com­
bined and washed with distilled H20 (2 x 150 ml) and satur­
ated NaCl solution (100 ml). The ethereal solution was dried 
(MgSO^) and concentrated to a viscous clear oil, 30.1 g (60%);
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TLC: Solv. A, Adsorb. A, Rf 0.74; [a]^5 15.3° (c 4.83, abs.
EtOH) ,* lit."^® (for the L derivative) -16.4° (abs. EtOH) .
L-Valine Methyl Ester Hydrochloride (53) . A solution 
of valine (40 g, 0.34 mol) in anhydrous methanol (600 ml) was 
heated to reflux and a stream of dry HC1 was bubbled through 
the reaction mixture. The addition of HC1 was continued at 
reflux for 4 hr and the solution was then cooled to 0°. When 
the cold solution became saturated with HC1 it was stoppered 
and placed in the refrigerator overnight. The solution was 
then concentrated to dryness and the residue was dissolved in 
methanol (100 ml) and concentrated to dryness again. This 
process was repeated three times and the residue was then 
dried in vacuo over KOH pellets. The product was recrys­
tallized from methanol (250 ml) by the addition of diethyl 
ether (450 ml) and cooling to -15° to give 41.0 g (mp 172- 
173°) of a white crystalline solid. An additional 8.5 g 
(mp 171-172°) was obtained from the mother liquors by con­
centrating and cooling. Both crops were combined and re­
crystallized from methanol (150 ml) by the addition of 
diethyl ether (400 ml) to yield 47.6 g (82%) of a white 
crystalline solid; mp 172-173°; [“ 1 ^  +15.0° (c 2, ^ 0 )
lit.104 mp 170°, [a]p5 +15.5° (c 2, HjO).
Benzyloxycarbonyl-D-leucyl-valine Methyl Ester (!54) .
A mixture of benzyloxycarbonyl-D-leucine (52^ ) (25.0 g, 0.094
mol), valine methyl ester hydrochloride (53^ ) (15.77 g, 0.094
mol), 1-hydroxybenzotriazole monohydrate (28.8 g, 0.188 mol) 
and N-methylmorpholine (9.5 g, 0.094 mol) in anhydrous THF
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was cooled to 0°. DCC (20.6 g, 0.100 mol) was added and the 
mixture was stirred first at 0° for 1 hr and then at room 
temperature for 2 hr. The precipitated DCU was removed by 
filtration and washed well with THF. The filtrate and wash­
ings were combined and concentrated. The residue was dissolved 
in ethyl acetate (400 ml) and filtered to remove more DCU. The 
filtrate was washed successively with distilled H20 (2 x 100 
m l), saturated NaHCO^ solution (2 x 100 m l), distilled H20 
(100 ml), 10% citric acid solution (2 x 100 ml), distilled 
H20 (100 ml) and saturated NaCl solution (100 ml). The ethyl 
acetate solution was dried (MgSO^) and concentrated to a 
yellow oil which solidified immediately. The solid was dis­
solved in ethyl acetate (100 ml) and filtered through a
4.5 x 15 cm column of basic alumina using ethyl acetate as 
the eluant (600 ml collected). The eluate was then concen­
trated to a volume of 150 ml, pentane (500 ml) was added, 
and the product was allowed to crystallize overnight. The 
product was filtered and dried to give 21.7 g of a white 
solid, mp 103-104.5°. An additional 7.5 g (mp 102-103.5°) 
was obtained from the mother liquor by concentrating and 
cooling. The resulting crude product was recrystallized 
from a minimum volume of ethyl acetate by the addition of 
5 volumes of pentane. Total yield, 29.2 g (82%); TLC:
Solv. A, Adsorb. A, Rf 0.87; [a]^5 32.7° (c 2, CHC13).
Anal. Calcd for G 2 oH 30N 2 ° 5 : C ' 6 3 -4 7 '* H ' 7 -99;
N , 4.70. Found: C, 63.40; H, 7.88; N, 7.44.
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Benzyloxycarbonylleucyl-D-leucyl-valine Methyl Ester 
(5j>) . Palladium on carbon catalyst (5%, 2.0 g) was added to 
a degassed solution (N2) of benzyloxycarbonyl-D-leucyl-valine 
methyl ester (54) (28.0 g, 0.074 mol) in methanol (400 ml)
containing distilled H20 (10 ml) and glacial acetic acid (10 
ml). The mixture was degassed again (N2) and hydrogenated at 
25 psi for 16 hr. The catalyst was removed by filtration 
through Celite and the filtrate was concentrated to a clear 
oil which was stored in vacuo for several hours to give the 
dipeptide methyl ester (5f3) as the acetate salt. The highly 
viscous oil obtained gave one ninhydrin positive spot on TLC 
analysis; 0.38 (Solv. B, Adsorb. A).
A solution of this oil (23.1 g) in anhydrous THF 
(2 00 ml) was cooled to 0° and N-methyl morpholine (9.1 g, 
0.091 mol) was added. To this stirred solution was added a 
solution of benzyloxycarbonyl-L-leucine (2JL) (20.0 g, 0.076
mol) and 1-hydroxybenzotriazole monohydrate (23.7 g, 0.155 
mol) in anhydrous THF (100 ml). DCC (16.5 g, 0.080 mol) was 
then added and stirring was continued at 0° for 1 hr and then 
at room temperature for 2 hr. The precipitated dicyclo- 
hexylurea (DCU) was filtered and washed well with THF. The 
filtrate and washings were combined and concentrated to an 
oil which was dissolved in ethyl acetate (250 m l), filtered 
to remove additional DCU and washed successively with dis­
tilled H20 (3 x 100 m l ) , saturated NaHCO^ solution ( 3 x 7 5  
ml), distilled H20 (100 ml), 10% citric acid solution (2 x 
75 ml), distilled H20 (100 ml) and saturated NaCl solution 
(5 0 ml). The organic phase was dried (MgSO^) and concen-
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trated to a volume of approximately 50 ml. The solution was 
filtered through a 4.5 x 2.5 cm column of basic alumina using 
ethyl acetate as the eluant (700 ml collected). The eluate 
was concentrated to 50 ml and pentane (500 ml) was added.
After 12 hr the crystalline solid was collected and dried,
19.8 g, mp 103-106°. An additional 2.0 g (mp 98-101°) was 
obtained by concentrating the mother liquors and crystallizing 
the resulting oily residue from ethyl acetate-pentane (1/10, 
v/v). Both solids were combined and recrystallized from ethyl 
acetate (75 ml) by the addition of pentane (400 ml) to give
14.1 g (39%) of a white crystalline solid, mp 119-120°;
25[a]D 24.5° (c 2, CHCl^). The mother liquors were concen­
trated to a clear oil which was purified by dry column 
chromatography on a 3 x 50 cm column of silica gel (Woelm) 
using chloroform-acetone (90/10, v/v) as the developing 
solvent. The desired tripeptide (_56) was extracted from the 
silica gel with diethyl ether. The ethereal extract was 
concentrated to a volume of 15 ml, pentane (100 ml) was 
added, and the product was allowed to crystallize. The 
product was filtered and dried to give 4.9 g (13.5%) of a 
white solid, mp 108-109.5°, 24.3° (c 2, CHCl^). Total
yield, 19.0 g (53%), TLC: Solv. B, Adsorb. A, 0.73;
Solv. C, Adsorb. A, 0.58.
Anal. Calcd for C2gH^^N^Og: C, 63.52; H, 8.40;
N, 8.55. Found: C, 63.13; H, 8.67; N, 8.51.
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Leucyl-D-leucyl-valine Methyl Ester 57^ . Palladium 
on carbon catalyst (5%, 1.0 g) was added to a degassed solu­
tion (N2) of benzyloxycarbonylleucyl-D-leucyl-valine methyl 
ester (_56) (16.3 g, 33 mmol) in methanol (200 ml), distilled
H20 (5 ml) and glacial acetic acid (4 ml). The mixture was 
degassed again (N2) and hydrogenated at 20 psi for 10 hr.
The catalyst was removed by filtration through Celite and the 
filtrate was concentrated to an oily foam. The foam was dis­
solved in ethyl acetate (200 ml) and washed with saturated 
NaHCO^ solution (2 x 25 ml) and distilled H20 (50 ml). The 
ethyl acetate solution was dried (MgSO^) and concentrated to 
a volume of 100 ml. Pentane (400 ml) was added and the 
product was allowed to crystallize at 0° for 24 hr. The 
product was collected and dried to give 7.7 g of a white 
cyrstalline solid, mp 142.5-143.5°. An additional 2.4 g 
(mp 142-143°) of product was obtained by concentrating and 
cooling the mother liquors. A total yield of 10.1 g (86%) 
was obtained; TLC: Solv. C, Adsorb. A, 0.31; Solv. E,
Adsorb. A, Rf 0.87; [ ot ] 32.3° (c 2, CH3OH) .
Anal. Calcd for C^3 H 3 5 N 3 ° 4 : c » 60.47; H, 9.87;
N, 11.76. Found: C, 60.40; H, 9.87; N, 11.60.
Benzyloxycarbonyl(y-tert-butyl)glutamate (58J. 
Compound 58^  was prepared by the procedure of Schwyzer and 
Kappeler^^^ and was isolated as its dicyclohexylamine salt, 
mp 139-140.5°; (ot]^5 6.6° (c 1.5, CH3OH) ; lit.105 mp 140- 
141°, [a]^5 7.2 + 0.7 (c 1.452, CH3OH).
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Benzyloxycarbonyl(y-tert-butyl)glutamyl-leucyl-D- 
leucyl-valine Methyl Ester (59) . A solution of benzyloxy- 
carbonyl-(Y-tert-buty])-glutamate dicyclohexylamine salt (15.0 
g, 29.0 mmol) in 50% ethanol (300 ml) was stirred with Dowex 
50W-X8 ion exchange resin, H+ form (29 ml, 55 meq) for 30 
min. The resin was filtered and the filtrate was concen­
trated to a volume of 150 ml. The mixture was extracted 
with ethyl acetate (3 x 75 ml) and the extracts were combined 
and washed with distilled H20 (50 ml). The ethyl acetate 
solution was dried (MgSO^) and concentrated to give compound 
58 as a colorless oil, 9.8 g (100%).
A solution of the above oil (9.8 g, 29 mmol), leucyl- 
D-leucylaline methyl ester (57) (10.0 g, 28.1 mmol) and 1-
hydroxybenzotriazole monohydrate (8.7 g, 56 mmol) in anhy­
drous THF (2 50 ml) was cooled to 0° and DCC (5.85 g, 28.3 
mmol) was added. The mixture was stirred first at 0° for 
1 hr and then at room temperature for 2 hr. The precipitated 
DCU was filtered and washed well with THF. The filtrate and 
washings were combined and concentrated to a yellow oil which 
was dissolved in ethyl acetate (250 ml). The ethyl acetate 
solution was filtered to remove additional DCU and was then 
washed successively with distilled H20 (2 x 100 m l), satur­
ated NaHCC>3 solution (3 x 100 ml) , distilled H20 (100 ml) ,
10% citric acid solution (100 m l ) , distilled H20 (100 ml) and 
saturated NaCl solution (50 ml). The organic phase was then 
dried (MgSO^) and concentrated to a volume of 25 ml. The 
oily solution was filtered through a 4.5 x 20 cm column of
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basic alumina using ethyl acetate as the eluant (650 ml 
collected). The ethyl acetate eluate was concentrated to 
75 ml and pentane (300 ml) was added. A white gel which 
formed immediately was broken up and stirred overnight. The 
gel was filtered and dried in vacuo to give a white solid.
The solid was triturated with a mixture of pentane and di­
ethyl ether (80:20, 200 ml) and the gelatinous residue was
filtered and dried in vacuo to give compound 5j) as a white
solid, 16.4 g (86%); mp 119-120°; TLC: Solv. A, Adsorb. A,
Rf 0.68; Solv. B, Adsorb. A, Rf 0.68; [a]^5 5.8° (c 2, CHC13).
Anal. Calcd for C^rH r.^NylO „ : C, 62.10; H, 8.34;  35 56 4 9
N, 8.28. Found: C, 61.99; H, 8.62; N, 8.37.
Amino acid ratio: Glu, 1.00; Leu, 1.99; Val, 1.01.
Attempted Preparation of Tetradepsipeptide 60.
Method A . A solution of compound !51 (1.20 g, 1.28 mmol) in 
anhydrous chloroform (7 ml) was cooled to 0°. A solution of 
HC1 in chloroform (0.33N, 0.5 ml) was added with stirring and 
the solution was allowed to warm to room temperature over a
15 min period. The solution was then concentrated to a 
yellow oil which was dissolved in diethyl ether (30 ml) and 
cooled to -15° for several hours. None of the desired hydro­
chloride salt (6 0*HC1) precipitated and the solution was 
concentrated again to a yellow oil. The oil was triturated 
with pentane but this failed to produce a solid product. The 
TLC of this oil (Solv. A, Adsorb. A) indicated a ninhydrin 
positive component (R^ 0.00-0.10) as well as some residual 
compound £0 (R^ 0.52) and o-nitrophenylsulfenyl chloride (R^
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0.93). Attempts to purify the slower running component (Rf 
0.00-0.10) by dry column chromatography on a 1.5 x 35 cm 
column of silica gel (Woelm) using chloroform-acetone (80/20, 
v/v) as the developing solvent led only to isolation of an 
oily mixture having several ninhydrin positive components, 
as revealed by ULC analysis (Solv. B, Adsorb. A ) .
A sample of this oil (0.53 g) was dissolved in di­
ethyl ether (2 5 ml) and washed with saturated NaHCO^ solu­
tion (2 x 25 ml), distilled 1^0 (25 ml) and saturated NaCl 
solution (25 ml). The organic phase was dried (MgSO^) and 
concentrated to a yellow oil (0.47 g) ; TLC,- Solv. B, Adsorb.
A, 0.64 (ninhydrin +) and R^ 0.95 (ninhydrin +).
Anal. Calcd for C 4 iH 6 9 N 4 °;lo : C ' 63-37; H ' 8 -82;
N, 7.21. Found: C, 57.60; H, 8.76; N, 6.30.
Method B . A solution of compound SI (0.235 g, 0.26
mmol), ammonium thiocyanate (0.043 g, 0.55 mmol) and 2-methyl-
indole (0.072 g, 0.55 mmol) in methanol-glacial acetic acid 
(1:1, 5 ml) was stirred for 4 hr at room temperature. The 
solution was then concentrated in vacuo and the only brown 
residue was dissolved in diethyl ether (25 ml) and washed 
with warm distilled H20 (3 x 50 ml) and 2.5% NH^OH solution 
(3 x 50 ml). The ethereal phase was dried (MgSO^) and con­
centrated to a brown oil (0.20 g); TLC: Solv. A, Adsorb. A,
R^ 0.93— identical to compound 51.
Method C . A solution of compound SI (0.233 g, 0.25
mmol) and thiophenol (0.08 ml) in dimethylformamide (5 ml) 
was stirred for 3 hr at room temperature. The solution was
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concentrated to an oily mixture; TLC analysis (Solv. A,
Adsorb. A) showed the mixture to be primarily compound 5_1 
(Rf 0.92).
Method D . A solution of compound 51 (0.117 g, 0.13 
mmol) in ice cold 88% formic acid (7 ml) was stirred at 0° 
for 3 hr. Distilled K^O (2.5 ml) was added and the mixture 
was concentrated to an oily residue. The residue was dis­
solved in ethyl acetate (15 ml) and washed with saturated 
NaHCO^ solution (10 ml) and distilled H20 (10 ml). The 
organic phase was dried and concentrated to a yellow oil 
which failed to yield a solid upon trituration with diethyl 
ether or with pentane. TLC analysis (Solv. F, Adsorb. A) 
indicated the oil was a mixture of several ninhydrin posi­
tive components.
Attempts to isolate compound 6£ as a solid oxalate 
by addition of an ethereal solution of anhydrous oxalic acid 
to an ethereal solution of the above oil failed to yield a 
pure solid derivative.
Benzyloxycarbonyl(y-tert-butyl)glutamyl-leucyl-D- 
leucyl-valine (63J . A solution of NaOH (0.94N, 2 0 ml) was 
added to a stirred solution of tetrapeptide methyl ester 5!J 
(4.0 g, 6.04 mmol) in 75% aqueous dioxane (120 ml). Stirring 
was continued for 35 min at room temperature and the solution 
was poured slowly into a vigorously stirred solution of ice- 
cold distilled H20 (600 ml) containing HC1 (1.18N, 17 ml).
The precipitated solid was collected, washed well with dis­
tilled H20 and dried in vacuo over KOH. It was then dissolved
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in a mixture of chloroform and ethanol (80/20, v/v) and 
filtered through a 4.5 x 10 cm column of silica gel (40-140 
mesh) using chloroform-ethanol (80/20, v/v) as the eluant 
(2 1 collected). The eluate was concentrated to a gel which 
was triturated with pentane and dried in vacuo to give tetra- 
peptide 61 as a white amorphous solid, 2.84 g (71%); mp 120-
130°; TLC: Solv. G, Adsorb. A, Rf 0.60;[a]^5 21.9° (c 2,
c h c i 3).
Anal. Calcd for C^Hj-^N^Og: C, 61.61; H, 8.21;
N, 8.45. Found: C, 60.88; H, 8.26; N, 8.67.
a-Methyl-g-tert-butyl Aspartate Hydrochloride (£2).
Compound 62^  was prepared by the procedure of Wttnsch and 
109Zwick and was isolated as a white crystalline solid; mp 
184-185°d,‘ [a]33 24. 6° (c 2, abs. EtOH)*, lit.109 mp 167°d, 
[a]35 25.8 + 0.5° (c 1.8, abs. EtOH).
Anal. Calcd for C9H15N04 •HC1: C, 45.09; H, 7.57;
N, 5.84. Found: C, 45.30; H, 7.66; N, 5.80.
Benzyloxycarbonyl(y-tert-butyl-glutamyl)leucyl-D- 
leucyl-valyl (a-methyl-B-tert-butyl) aspartate (63J . A mixture 
of tetrapeptide 6_1 (1.36 g, 2.04 mmol), a-methyl-8-tert-butyl 
aspartate hydrochloride (62) (0.49 g, 2.04 mmol) and 1-
hydroxybenzotriazole monohydrate (0.62 g, 4.08 mmol) in 
anhydrous THF (20 ml) was cooled to 0°. To this stirred 
solution was added DCC (0.43 g, 2.08 mmol) followed by N- 
methyl morpholine (0.2 03 g, 2.06 mmol). Stirring was con-
154
tinued for 1 hr at 0° and then for 4 hr at room temperature. 
The reaction mixture was then filtered and the residue was 
washed well with THF. The filtrate and washings were combined 
and concentrated to dryness. The residue wad dissolved in 
warm ethyl acetate (75 ml) and washed successively with dis­
tilled H20 (2 x 25 ml), saturated NaHCO^ solution (2 x 25 ml), 
distilled H20 (25 ml), 10% citric acid solution (2 x 25 ml) 
and distilled H20 (25 ml). The organic phase was dried 
(MgSO^) and concentrated to dryness. The residue was dis­
solved in a minimum volume of hot ethyl acetate and filtered 
through a 4.5 x 25 cm column of basic alumina using ethyl 
acetate as the eluant (700 ml collected). The eluate was 
concentrated to dryness and the residue was dissolved in 
warm ethyl acetate (35 ml). After standing at room temper­
ature for 12 hr the insoluble material was filtered off and 
washed with ethyl acetate. The filtrate and washings were 
combined and concentrated to dryness and the residue was 
triturated with pentane to give compound 6_3, 1.11 g (65%); 
mp 186-190°; TLC; Solv. A, Adsorb. A, Rf 0.61; [a]^5 18.1°
(c 2, CHC13).
Anal. Calcd for C43Hg9N5°^2: C ' ^0.90; H ' 8.20;
N, 8.26. Found: C, 60.84; H, 8.15; N, 8.19.
Amino acid ratio: Asp, 1.02; Glu, 1.03; Leu, 1.94;
Val, 1.00.
Benzyloxycarbonyl(y-tert-butyl)glutamyl-leucyl-D-
leucyl-valyl (6-tert-butyl)aspartate (64). A solution of NaOH 
(0.94N, 6.77 ml) was added to a stirred solution of penta-
155
peptide 6J3 (1.74 g, 2.05 mmol) in 75% aqueous dioxane (60 ml). 
The solution was stirred for 23 min at room temperature and 
was then poured slowly into a vigorously stirred solution of 
ice-cold distilled (250 ml) containing HC1 (1.18N, 5.5 ml).
The precipitated solid was collected, washed well with dis­
tilled H20 and dried in vacuo over KOH pellets.
The resulting solid was dissolved in a minimum amount 
of chloroform-ethanol (80/20, v/v) and the solution was 
filtered through a 4.5 x 25 cm column of silica gel (40-140 
mesh) using chloroform-ethanol (80/20, v/v) as the eluant 
(2 L collected). The eluate was concentrated to a gel-like 
solid which was triturated with pentane and dried to give 
compound <54 as a white solid, 1.40 g (82%); mp 179-181°;
TLC: Solv. G, Adsorb. A, Rf 0.59; ta]^5 -19.2° (c 2, CHC13).
Anal. Calcd for C42H67N5°i2: C ' 60.48; H, 8.10;
N, 8.40. Found: C, 60.22; H, 8.15; N, 8.67.
The Preparation of Octadepsipeptide 65^ . The same 
procedure was employed as was used for compound 66^  (see 
following description) using pentapeptide 6j4 (0.746 g, 0.894
mmol) and tridepsipeptide 44_ (0.542 g, 0.894 mmol). Compound
65 was obtained as a white solid, 0.71 g (60%); mp 175-178°; 
TLC: Solv. A, Adsorb. A, Rf 0.87; [a]^5 2.1° (c 2, CHC13).
Anal. Calcd for C75H12qN8C>18: C, 63. 35; H, 8.51;
N, 7.88. Found: C, 63.05; H, 8.43; N, 7.99.
Amino acid ratio: Asp, 1.01; Glu, 0.99; Leu, 3.99;
Val, 1.01.
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The Preparation of Octadepsipeptide 66^ A solution 
of pentapeptide 6£ (0.501 g, 0.60 mmol), tridepsipeptide 45^  
(0.364 g, 0.60 mmol) and 1-hydroxybenzotriazole monohydrate 
(0.184 g, 1.20 mmol) in anhydrous THF (50 ml) was cooled to 
0° with stirring. DCC (0.128 g, 0.62 mmol) was then added 
and stirring was continued at 0° for 1 hr and at room temp­
erature for 5 days. The reaction mixture was then filtered 
and the residue was washed well with THF. The filtrate and 
washings were combined and concentrated to dryness. The 
residue was dissolved in ethyl acetate (200 ml) and washed 
successively with distilled H 2 O (2 x 100 m l), saturated 
NaHCO^ solution (2 x 100 ml), 10% citric acid solution (2 x 
100 ml), distilled (100 ml) and saturated NaCl solution
(100 ml). The organic phase was dried (MgSO^) and concen­
trated to a gelatinous residue which was dissolved in a 
minimum volume of warm ethyl acetate and filtered through a
4.5 x 25 cm column of basic alumina using ethyl acetate as 
the eluant (800 ml collected). The eluate was concentrated 
to a gelatinous residue which was dissolved in a minimum 
volume of ethyl acetate. The solution was allowed to stand 
and the insoluble material was filtered. The filtrate was 
concentrated to a gel which was triturated well with pentane 
and dried. The solid was reprecipitated from hot ethyl 
acetate (25 ml) by the addition of pentane (2 00 ml). The 
resulting gel was collected and dried to give compound 66^  
as a white solid 0.64 g (75%); mp 154-156°; TLC: Solv. A,
Adsorb. A, Rf 0.75; [ct]^5 30.1° (c 2, CHC13).
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Anal. Calcd for C75Hi20N 8°18: C ' 63*35'* H ' 8.51;
N , 7.88. Found: C, 63.26; H, 8.40; N, 7.90.
Amino acid ratio: Asp, 1.00; Glu, 1.00; Leu, 3.97;
Val, 1.03.
The Preparation of Octadepsipeptide 61_. Palladium 
on carbon catalyst (5%, 0.05 g) was added to a degassed 
solution (N2) of compound 66^  (0.50 g, 0.35 mmol) in methanol 
(35 ml). The solution was degassed again (N2) before hydrog­
enating at atmospheric pressure for 12 hr. The catalyst was 
then removed from the mixture by filtration through Celite 
and the filtrate was concentrated to dryness. The residue 
was triturated repeatedly with pentane (6 x 50 ml) and dried 
to give compound 6J7 as a white solid, 0.380 g (94%); mp 
134-137 ; TLC: Solv. H, Adsorb. A, 0.87; Solv. G, Adsorb.
A; Rf 0.90, [a]^5 51.0° (c 1, CHC13).
Anal. Calcd for cgoH109N7°14: C ' ^2.52; H ' 9.53;
N, 8.51. Found: C, 61.85; H, 9.86; N, i.53.
The Preparation of Cyclooctadepsipeptide 6j8. A 
solution of compound (57 (0.3 69 g, 0.320 mol) in anhydrous 
dimethylformamide (5.0 ml) was diluted with anhydrous 
methylene chloride (170 ml). N-Hydroxysuccinimide (0.150 g,
1.30 mmol) was added with stirring and the solution was 
cooled to 0°. DCC (0.181 g, 0.88 mmol) was added and 
stirring was continued for 6 hr at 0° and then for 3 days 
at room temperature. The solution was then concentrated 
to dryness. The residue was dissolved in ethyl acetate 
(5 ml) and concentrated to dryness again. This process
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was repeated twice and the resulting residue was purified 
by column chromatography on a 4 x 45 cm column of silica gel 
(100-200 mesh) using chloroform-acetone (80/20, v/v) as the 
eluant. The fractions containing the desired product (R^ 
0.64, TLC Solv. A, Adsorb. A) were combined and concentrated 
to dryness.
The residue was dissolved in ethyl acetate (0.25 ml) 
and pentane (20 ml) was added. The solution was cooled to 
-15° for several hours. The precipitated solid was collected 
and dried to give 0.190 g (52%) of a white solid. This 
solution was purified further by high pressure gel permeation 
chromatography on a 4 ft x 3/8 in. Poragel 60 A (Waters) 
column using ethyl acetate as the eluant. The fractions 
having a retention volume of 24 ml were collected, pooled 
and concentrated to dryness. The residue was crystallized 
from ethyl acetate (0.25 ml) by the addition of pentane (20 
ml) with cooling to give the protected cyclooctadepsipeptide 
68 as a white solid, 0.149 g (40%); mp 129-131°; TLC: Solv.
A, Adsorb. A, 0.65; -25.4° (c 1, CHCl-j), ir spec.
no. 22111 (nujol) 3300 cm ^ (N-H), 1735, 1720 (C=0, ester, 
lactone), 1650 (amide I), 1535 (amide II).
Anal. Calcd for : C, 63.52; H, 9.51;
N, 8.64. Found: C, 63.79; H, 9.56; N, 8.78.
Amino acid ratio: Asp, 0.99; Glu, 0.98; Leu, 4.05;
Val, 0.94.
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Norsurfactin (11). A solution of compound £8 (90 
mg, 0.079 mmol) in anhydrous trifluoroacetic acid (0.7 ml) 
was stirred for 30 min at room temperature. The solution 
was concentrated and the residue was stored in vacuo over 
KOH for several hours. It was purified by preparative layer 
chromatography on three 20 x 20 cm silica gel plates using 
ethyl acetate-acetic acid-water (18:6:6). The product (Rf
0.8-0.85) was extracted from the silica gel using ethyl 
acetate. The extract was concentrated and the residue was 
further purified using high pressure liquid chromatography
on a 4 ft. x 3/8 in. C^g/Porasil B (Waters) column using
acetonitrile-water (80:20) as the solvent. The product 
with retention volume 735 ml (after 2 recycles) was collected. 
After concentration of the solvent the resulting residue was 
dissolved in ethyl acetate and precipitated by the addition 
of pentane. The solid product was collected and dried to 
give norsurfactin, 51 mg (65%); mp 138-142°; 27.1°
(c 1, CHClg), -35° (c 1, CHgOH); ir spec, no. 22117 (KBr) 
3200-3500 cm ^ (N-H, O-H), 1735 (C=0, lactone), 1660 (amide 
I), 1540 (amide II); TLC*: Solv. H, Adsorb. A, Rf 0.43;
Solv. I, Adsorb. A, R^ 0.80; Solv. J, Adsorb. A, R^ 0.81;
Solv. K, Adsorb. A, R^ 0.73.
Anal. Calcd for C52HgiN7C>3 : C, 61.09; H, 8.97;
N, 9.59. Found: C, 60.77; H, 9.03; N, 9.30.
*R^ values given are for the major component. In some
solvent systems minor impurities having lower R^ values 
were still evident.
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Amino acid ratio: Asp, 0.97; Glu, 1.01; Leu,
Val, 0.99.
Lit.22 for surfactin; mp 140-141°,* [a]2  ^ 40° ( 
CHC13), -39° (c 1, CH30H), TLC: Solv. I, Adsorb. A, R
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